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2BAbstract 
Cardiomyocyte contraction is controlled by intracellular Ca
2+
 concentrations. 
Action potential opens the voltage-gated calcium channel in the sarcolemma and triggers 
the calcium-induced calcium-release mechanism to release Ca
2+
 stored in the 
sarcoplasmic reticulum (SR) through ryanodine receptors. For muscle relaxation to occur, 
Ca
2+
 must be removed from the cytosol. Most of the activator Ca
2+
 is sequestered back 
into the SR by sarco(endo)plasmic reticulum Ca
2+
-ATPase (SERCA). In ventricular 
myocytes, SERCA is regulated by a small integral membrane protein, phospholamban 
(PLB). PLB binds and inhibits SERCA, and this inhibition is physiologically relieved by 
either micromolar Ca
2+
 in systole, or by phosphorylation at Ser16 or Thr17 through -
adrenergic stimulation. A decline in SERCA activity is implicated in heart failure 
irrespective of etiologies. Recent gene therapies for heart failure emphasize enhancing 
SERCA activity by decreasing PLB inhibition. However, the structural mechanism of 
relief of inhibition still remains elusive. This thesis work is motivated to elucidate the 
structural basis for SERCA regulation by PLB, hence providing more information for the 
design of next generation gene and drug therapies. 
This thesis work uses time-resolved fluorescence resonance energy transfer (TR-
FRET) to probe the structures of the SERCA-PLB complex in its activated or inhibited 
forms. In the first project, we investigated the function effect of the equilibrium of PLB 
cytoplasmic domain between an ordered R state and a disordered T state on SERCA 
regulation. We varied the lipid headgroup charges to perturb this equilibrium through 
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electrostatic interactions with the positively charged PLB cytoplasmic domain. TR-FRET 
measurements, in conjunction with functional data and electron paramagnetic resonance 
experiments, established the correlation of the T/R equilibrium with PLB inhibitory 
potency. In the second project, we studied the structures of the SERCA-PLB complex 
under physiological conditions that relieve inhibition. TR-FRET distance measurements 
between cytoplasmic domains of SERCA and PLB revealed that phosphorylation of PLB 
at Ser16 relieves SERCA inhibition mainly by shifting the T/R equilibrium toward the 
less inhibitory R state, and partially by dissociating the complex. Micromolar Ca
2+
 
probably relieves inhibition through structural rearrangements within the transmembrane 
domain of the complex. In the last project discussed in this thesis, we used western blot to 
quantify different phosphorylation states of PLB in pig cardiac SR. PLB can be 
phosphorylated at either Ser16 or Thr17, generating four phosphorylation states: 
unphosphorylated, phosphorylated only at Ser16, phosphorylated only at Thr17, or 
phosphorylated at both sites. We also found that each PLB phosphorylation state has a 
distinct inhibitory potency for SERCA. 
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7BChapter 1 Introduction 
13B .1 Calcium Cycling in Cardiomyocytes 
In cardiomyocytes, when the action potential depolarizes the sarcolemma in T-
tubules, Ca
2+
 enters the cytoplasm mainly through membrane-potential dependent L-type 
calcium channels (Figure 1), contributing to the early phase of the action potential 
plateau. The sodium calcium exchanger (NCX), residing on sarcolemma, may also 
contribute a small portion of Ca
2+
 influx with concurrent countertransport of Na
+
. [2] The 
influx of Ca
2+
 raises the cleft Ca
2+
 concentration, which activates ryanodine receptors 
(RyRs) to release Ca
2+
 from the sarcoplasmic reticulum (SR). This is the calcium-induced 
 
Figure 1 Calcium cycling in ventricular cardiomyocytes. Ca
2+
 enters the cell during action 
potential, and triggers Ca
2+
 release from the SR by calcium-induced calcium release mechanism. 
Elevated cytosolic Ca
2+
 concentration triggers the muscle contractile machinery. Activator Ca
2+
 is 
sequestered into the SR by SERCA, extruded by NCX on sarcolemma and plasma membrane 
Ca
2+
-ATPase, and imported into mitochondria by a Ca uniporter. Figure taken from [1]. 
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calcium-release mechanism. Approximately 50-60% of the total SR Ca
2+
 is released and 
the cleft [Ca
2+
] is raised to 200-300 µM. [3] Ca
2+
 diffuses from the cleft to the cytosol 
and binds to troponin C (TnC), which triggers the conformational change of the 
troponin/tropomyosin complex, exposing the myosin binding sites on actin. The myosin 
head then binds to and pulls actin at the expense of ATP, causing muscle contraction.  
For muscle relaxation to occur, Ca
2+
 needs to be removed from cytosol. This is 
achieved through sarco(endo)plasmic reticulum Ca
2+
-ATPases (SERCA), NCX, plasma 
membrane Ca
2+
-ATPase (PMCA), and Ca
2+
 uniporter on mitochondria (Figure 1). In 
murine ventricles, 90-95% of the activator Ca
2+
 is removed by SERCA, and only 5-8% 
by NCX. In contrast, in ventricles of rabbit, dog, cat, guinea pig, ferret, and human, the 
breakdown is 70% by SERCA and 25-28% by NCX. [1] 1% is extruded from the cytosol 
by PMCA. The remaining 1% is imported by a Ca
2+
 uniporter into mitochondria, where 
Ca
2+
 regulates ATP production. [4]  
 
14B .2 SERCA 
SERCA is a P-type ATPase localized both in endoplasmic reticulum (ER) and SR. 
In muscle cells, SERCA harnesses the energy in the -phosphate of ATP and actively 
transports Ca
2+
 across the SR membrane against the concentration gradient at an 
approximate rate of 2 Ca
2+
 per ATP hydrolyzed. In mammals, three genes encode 
SERCA, namely SERCA1, SERCA2 and SERCA3, producing more than 10 isoforms. 
[5] SERCA1a is expressed in adult fast-twitch muscle. [6,7] SERCA2a is predominantly 
expressed in cardiac muscle and slow-twitch skeletal muscle. [8,9] SERCA3 isoforms are 
ubiquitously expressed in both nonmuscle and muscle tissue. [10,11] Both the structure 
and function of SERCA isoforms are highly conserved. SERCA2a protein is about 84% 
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identical to SERCA1a protein, and these two isoforms are functionally identical. Both of 
them can be regulated by phospholamban (PLB), which is an endogenous inhibitor of 
SERCA2a. SERCA1a and SERCA2a also have similar affinity for Ca
2+
, maximum 
velocity of Ca
2+
 uptake and pH dependence [12]. SERCA1a is predominantly used in in 
vitro studies because of its abundance relative to SERCA2a in muscle tissue. 
SERCA1a consists of ten transmembrane helices (M1-M10) and three cytoplasmic 
domains: the actuator (A) domain, the nucleotide-binding (N) domain, and the 
phosphorylation (P) domain (Figure 2). [13] The first crystal structure of SERCA with 
two Ca
2+
 ions bound was not obtained until 2000 by Toyoshima’s group. [15] Since then, 
a plethora of SERCA crystal structures stabilized with inhibitors and substrate analogues 
Sarco(endo)plasmic reticulum calcium ATPase 
(SERCA)
E2-Tg 
Toyoshima, 2002 
• P-type ATPase
• Active reuptake of Ca2+ to induce 
muscle relaxation
• 10 transmembrane helices and 3 
cytoplasmic domains
• SERCA is regulated by 
phospholamban (PLB) in the heart
A
N
P
 
Figure 2 Crystal structure of SERCA. (1IWO). SERCA consists of ten transmembrane helices 
(grey) and three cytoplasmic domains, namely nucleotide-binding domain (green), actuator 
domain (red), and phosphorylation domain (blue). This crystal structure is stabilized by 
thapsigargin (purple). Structure resolved in [13] and rendered in VMD [14]. 
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has been obtained. [13,16,17,18,19,20] These crystal structures constitute a whole 
spectrum of SERCA catalytic intermediates, laying the structural foundation for probing 
calcium transport mechanism. 
During an enzymatic cycle, SERCA transports 2 Ca
2+
 and countertransports 2-3 
protons with 1 ATP hydrolyzed. [21] SERCA alternates between E1 (with high affinity 
for Ca
2+
) and E2 (with high affinity for protons) intermediates in a cyclical manner. 
Recent crystal structures suggest that under physiological conditions, all intermediates 
have bound nucleotide, leading to a revised scheme of SERCA Ca
2+
 transport cycle 
(Figure 3). [22] The Ca
2+
 transport cycle starts with the transition from a proton-bound 
non-phosphorylated E2 state (HnE2:ATP) to a calcium-bound E1 intermediate (Ca2E1-
ATP). The binding of 2 cytosolic Ca
2+
 is accompanied by the release of 2-3 protons. The 
transporter then rapidly autophosphorylates Asp351, forming a high-energy 
phosphorylated [Ca2]E1~P:ADP intermediate with occluded Ca
2+
. This is followed by the 
conformational change of SERCA back to the E2 state, the low-energy phosphorylated 
[Ca2]E2P:ATP form. [23] ADP, the product of the autophosphorylation reaction, is 
replaced by ATP at this step. In the next step, Ca
2+
 is released into the SR lumen in 
exchange of 2-3 protons, forming HnE2P:ATP intermediate. After closure of the luminal 
channel, these protons are occluded inside the transmembrane domain in the  
[Hn]E2-P:ATP transition state. Finally, the ATPase releases the phosphate and returns to 
the starting state. 
  5 
  
 
Figure 3 SERCA enzymatic cycle represented by SERCA1a crystal structures. The 
enzymatic cycle consists of the following reactions: (1) the exchange of protons for cytoplasmic 
Ca
2+
 ions; (2) phosphorylation at Asp351; (3) the conversion of [Ca2]E1~P:ADP to 
[Ca2]E2P:ATP (the structure of the latter is still unknown); (4) exchange of Ca
2+
 with luminal 
protons; (5) the formation of the proton occluded transition state; (6) the release of phosphate 
group. Figure taken from [22]. 
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15B .3 Phospholamban (PLB) 
Phospholamban is an endogenous inhibitor of SERCA2a in cardiac and slow-twitch 
skeletal muscle. [24,25,26] Unphosphorylated PLB inhibits SERCA by decreasing its 
apparent Ca
2+
 affinity. [27] This inhibition is relieved either by micromolar Ca
2+
 or by 
phosphorylation of PLB. Two sites on PLB can be phosphorylated under physiological 
conditions. One is Ser16 which is phosphorylated by cAMP-dependent protein kinase A 
(PKA), and the other is Thr17 by calcium/calmodulin-dependent protein kinase II 
(CaMKII).  
Wild-type PLB equilibrates between monomers and homopentamers, which are 
stabilized by a leucine-isoleucine zipper. [29,30,31] Shifting the equilibrium toward the 
Text
1
Ia
(II)
Ib
52
 
Figure 4 NMR structure of monomeric PLB.PLB consists of domain Ia (yellow), loop (red), 
domain Ib (grey) and domain II (blue). The three cysteine residues in the transmembrane domain 
are mutated to alanine, phenylalanine and alanine (orange) to prevent formation of PLB 
homopentamer. Structure resolved in [28] and rendered in VMD [14]. 
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monomers is positively correlated with SERCA inhibition, suggesting that the 
monomeric form is the active species. [32,33,34,35,36] The pentamer is considered to be 
a storage or buffer form for the active monomers, although an electron microscopy study 
showed physical interaction between pentameric PLB and SERCA. [37] To eliminate 
PLB-PLB interactions and simplify SERCA-PLB measurements in our experiments, I 
used a monomeric form of PLB, with the three cysteines mutated to Ala, Phe and Ala, 
respectively (Figure 4). Electrophysiological studies suggested that pentameric PLB is an 
ion channel [38,39], but this is contradicted by NMR structures showing that the pore 
formed by PLB pentamer is not large enough to accommodate ions [40,41].  
Mutagenesis studies at cardiomyocyte, organ, and intact animal levels found that 
phosphorylation of PLB by PKA at Ser16 and by CaMKII at Thr17 is the major mediator 
of the positive inotropic and lusitropic effects of the 1-adrenergic stimulation in the 
mammalian heart. [42,43,44] The increase in SERCA2a activity and Ca
2+
 uptake elicited 
by phosphorylation of these sites, leads to an increase in the rate of muscular relaxation, 
SR Ca
2+
 load, and SR Ca
2+
 release. In association with L-type Ca
2+
 channel and RyR2 
phosphorylation, these processes mediate the enhanced contractility produced by 1 
stimulation. [42]. 
Ser16 was believed to be the predominant phosphorylation site in the 1-adrenergic 
response. Phosphorylation at Ser16 was sufficient in mediating the maximal cardiac 
response to -agonists. [45,46] Additional phosphorylation at Thr17 phosphorylation did 
not further activate SERCA. [47] Studies using mice with CaMKII inhibition showed 
unaltered response to isoproterenol. [48] However, the importance of Thr17 
phosphorylation was found under pathological conditions, including ischemia-reperfusion 
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injuries, hypercapnic acidosis, and stunned hearts. [42,49] The two prerequisites for 
Thr17 phosphorylation are (a) stimulation of CaMKII signaling pathways and (b) 
inhibition of protein phosphatase 1, which dephosphorylates PLB at both Ser16 and 
Thr17. The above mentioned pathological situations activate CaMKII by increasing 
intracellular [Ca
2+
] and acidosis-induced phosphatase inhibition. [49] Thr17 
phosphorylation, but not Ser16 phosphorylation, was found to increase transiently during 
the early phase of reperfusion in ischemia/reperfusion injuries, and at the onset of 
acidosis. [50,51,52] Further mutagenesis studies used mice with S16A (not 
phosphorylatable at Ser16) and T17A (not phosphorylatable at Thr17) mutants. They 
demonstrated that Thr17 phosphorylation was essential for recovery of Ca
2+
 transients 
and contractility in the stunned heart. [52,53] 
However, quantitation and systematic study of the inhibitory potency of different 
phosphorylation states of PLB are still lacking. In Chapter 5, we used quantitative 
western blot to measure the levels of PLB in pig cardiac SR. We also used an enzyme-
coupled assay to measure the SERCA inhibition by different phosphorylation states of 
PLB in a controlled environment.  
16B .4 The SERCA-PLB Complex 
The structure of the SERCA-PLB complex has been probed with various 
experimental methods, but the high-resolution crystal structure is still elusive. Early 
attempts were made with crosslinking and mutagenesis studies. James et al used a cross-
linking agent and showed that K3 of PLB lies within 15 Å of both K397 and K400 in the 
sequence Lys-Asp-Asp-Lys-Pro-Val-402 in the N domain of SERCA2a, which was later 
confirmed by a mutagenesis study. [54,55] In the SERCA transmembrane domain, 
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mutations in M4 and M6 were found to have diminished ability to interact functionally 
with PLB. [56] On the PLB side, charged and hydrophobic residues from Glu2 to Ile18 in 
the cytoplasmic domain are essential for functional regulation of SERCA. [57,58] The 
transmembrane domain of PLB is sufficient to inhibit SERCA. [59,60] Mutations on one 
side of the transmembrane domain frequently disrupt its interaction with SERCA, and 
mutations on the other side eliminate the ability to form pentamers, although some 
residues forming the leucine/isoleucine zipper were also shown to interact with SERCA 
residues. [31,61,62,63,64] Several low resolution cryo-EM structures have been 
published, with varying SERCA to PLB stoichiometry of the complex. [30,37] 
Based on constraints given by a plethora of SERCA crystal structures, mutagenesis 
and cross-linking studies, two computational models of the SERCA-PLB complex were 
proposed. These two models are very similar, with the one from Toyoshima’s group 
BA C
 
Figure 5 Structures of SERCA-SLN and SERCA-PLB complexes. A. Computational model of 
the SERCA-PLB complex. SERCA is shown in green and PLB in orange. Figure from [65]. B. 
Crystal structure of the SERCA-SLN complex. Sarcolipin (SLN) is shown in cyan. Figure from 
[66]. C.Crystal structure of the SERCA-PLB complex. Figure from [67]. The PLB that interacts 
with SERCA is shown in magenta. A small portion of the transmembrane domain of a second 
PLB (yellow) is also observed in the electron density. 
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receiving more NMR experimental support. [65,68,69,70] In this model (Figure 5A), the 
transmembrane domain of PLB lies in a groove formed by M2, M4, M6 and M9 of 
SERCA, and the cytoplasmic domain lies in the hydrophobic groove in the N domain, as 
previously determined by the cross-linking study. [54,65] The cytoplasmic domain of 
PLB was unwound and extended to fit steric and biochemical constraints. Both of these 
models predict that PLB binds the E2 form of SERCA, the reason being that the binding 
groove on SERCA’s transmembrane domain is closed in E1·Ca2 form. The crystal 
structures of SERCA in complex with sarcolipin (SLN), a homologue to the PLB 
transmembrane domain present in heart atria and fast-twitch skeletal muscles, were 
published simultaneously by two groups (Figure 5B). [66,71] The two co-crystal 
structures of SERCA-SLN found that SLN binds in a groove formed by M2, M6, and 
M9. This is the same groove predicted by the previous SERCA-PLB computational 
model, and confirmed later by a crystal structure of SERCA in complex with a 
superinhibitory PLB mutant (PLB4) (Figure 5C). [65,67] However, in this crystal 
structure, only a portion of the transmembrane domain of PLB4 was resolved. The 
cytoplasmic domain as well as the C-terminus was not visible by electron density 
mapping. This structure also showed a small fragment of a second PLB4 tagging along 
with the PLB4 which physically interacts with SERCA. In all these structures, SLN and 
PLB bind to SERCA at the same site and trap SERCA into a previously unknown 
structure, more resembling the E1 state than the E2 state.  
The structural mechanism of SERCA regulation by PLB remains controversial. The 
canonical “Dissociation Model” states that PLB binds SERCA to inhibit it, and 
dissociates from SERCA to relieve inhibition. This model was supported by crosslinking 
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and co-immunoprecipitation studies showing that either Ca
2+
 alone, or phosphorylation at 
Ser16 alone, or the combination of both, decrease physical interaction between SERCA 
and PLB.[54,72,73,74,75,76,77] However, new spectroscopic studies suggested the 
“Subunit Model”, where neither Ca2+ nor phosphorylation of PLB dissociate the 
complex, but rather induce structural rearrangements within the complex. Specifically, 
EPR and NMR studies found that the cytoplasmic domain of PLB exists in a dynamic 
equilibrium between two states, an ordered T state, and a disordered R state. 
[78,79,80,81,82] Shifting the equilibrium toward R state by phosphorylation at Ser16, 
PLB mutants, or charged lipids, is sufficient to relieve inhibition. [82,83,84] The relief of 
inhibition by micromolar Ca
2+
 does not require dissociation either. FRET between 
SERCA and PLB showed little or no dissociation caused by Ca
2+
. [85,86] Crosslinking 
and crystallography studies showed that PLB and SLN bind to the same groove on the 
SERCA transmembrane domain. [66,67,71,77] Two recent crosslinking studies found 
that SLN remains bound to SERCA throughout the enzymatic cycle. [76,77] It is thus 
proposed that SLN undergoes positional rearrangement to avoid clashes with the binding 
groove on SERCA in the calcium bound form. [66] It is possible that as the conformation 
of SERCA accommodates the binding of SLN and PLB in the absence of Ca
2+
, the 
conformation of SERCA would also adapt to accommodate PLB in the presence of Ca
2+
. 
The transmembrane domain of PLB probably repositions in a similar fashion as SLN, 
which explains the absence of dissociation between SERCA and PLB detected by FRET 
at high [Ca
2+
]. [85,86] The local rearrangement is probably specific to each protein, 
which may explain the decreased crosslinking from PLB homologous site to SERCA 
[72,73,76]. 
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To elucidate the structural basis for SERCA regulation by PLB and to test whether 
dissociation is necessary for relief of inhibition, we used charged lipids (Chapter 3), 
phosphorylation at Ser16 of PLB, and Ca
2+
 (Chapter 4) to perturb the function of the 
SERCA-PLB complex. TR-FRET revealed that the activity of SERCA-PLB complex is 
mainly controlled by the T/R equilibrium of the PLB cytoplasmic domain. 
17B .5 Heart Disease and the SERCA-PLB Complex 
No SERCA mutation has been found to be directly correlated to human heart 
disease. But genetic variance of the PLB gene underlies several forms of human 
cardiomyopathy, although the frequency in the population is rare. Abnormal PLB level is 
probably a cause of cardiac malfunction. The first reported mutation in the PLB promoter 
region was found in a Japanese female patient with familial hypertrophic 
cardiomyopathy, probably due to increased transcriptional activity caused by this point 
mutation. [87] Later, another point mutation causing enhanced promoter activity was 
identified in Caucasian and Greek patients with dilated cardiomyopathy. [88] A case of a 
2.5 year old girl with dilated cardiomyopathy was reported earlier this year, and genetic 
testing found chromosome duplication, where PLB was included. [89] Decreased PLB 
levels are also pathogenic. The PLB promoter mutant with decreased transcriptional 
activity was linked to late-onset hypertrophic cardiomyopathy in a Spanish family. [90] A 
virtually PLB null phenotype was discovered in two Greek families with inherited dilated 
cardiomyopathy. This point mutation results in L39Stop with absence of expression. [91]  
Dominant R9C missense mutation was found to be correlated with inherited 
human dilated cardiomyopathy. Transgenic PLN-R9C mice recapitulated human heart 
failure with premature death. [92] Later, mutations at R9, R9L and R9H, were found to 
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be related to dilated cardiomyopathy in Brazilian population. [93] Detailed biochemical 
and biophysical studies found that R9C, R9L and R9H all elude phosphorylation by 
PKA, and R9C and R9L do not inhibit SERCA. [94,95] R9C was also found to stabilize 
the PLB pentamer by formation of disulfide bonds and eludes PKA phosphorylation. [95] 
Another study attributed the disease-causing ability of lethal R9C, R9L, R9H and R14del 
to hydrophobicity imbalance of PLB cytoplasmic domain. [58] R14del was found in 
patients with inherited dilated cardiomyopathy in Greek and German populations.[96,97] 
A later study using a transgenic mouse model found that R14Del is misrouted to the 
sarcolemma, where it activates Na/K-ATPase, leading to the activation of cardiac 
remodeling pathways. [98] 
Calcium mishandling is one of the prominent features of heart failure, partially 
due to decreased SERCA2a activity regardless of heart failure etiology. [99,100,101,102] 
The failing heart expresses lower levels of SERCA2a [1,27]. SERCA2a activity is further 
decreased by increased inhibition of PLB due to (a) PLB protein levels decreased by a 
smaller proportion than the protein levels of SERCA in the failing hearts, therefore the 
ratio of PLB to SERCA increased [101,103]; and (b) the phosphorylation level is also 
decreased in human failing myocardium, either at Ser16 [104,105], Thr17 [106], or both 
[107,108]. Enhancing SERCA2a activity to restore Ca
2+
 homeostasis has been one of the 
primary targets of the recent gene therapies for heart failure. Moreover, these gene 
therapies showed promising results in both human patients and animal heart failure 
models. 
One strategy to enhance SERCA2a activity is to directly increase SERCA2a 
expression in failing hearts. SERCA2a gene transfer in a number of heart failure models 
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showed preservation of systolic function and improvement of ventricular remodeling 
[109], restoration of the normal state of cardiac energetics [110,111], decrease in 
ventricular arrhythmias [112,113,114,115], and enhancement of coronary flow through 
activation of eNOS in endothelial cells [116]. CUPID (The Calcium Up-Regulation by 
Percutaneous Administration of Gene Therapy In Cardiac Disease) study is a first-in-
human clinical gene therapy trial using an adeno-associated virus serotype (AAV1) 
vector to deliver SERCA2a gene in patients with advanced heart failure. It now has 
progressed to phase IIb clinical trial. [117] Lower number of cardiovascular events and 
significantly decreased risk of recurrent cardiovascular events were found in the group of 
patients who received high-dose of SERCA2a gene. No safety concerns were noted 
during the 3-year follow-up. [118] The success of these animal and human studies further 
validates SERCA2a as a promising therapeutic target for heart failure. 
Another strategy to enhance SERCA2a activity is to decrease inhibition by PLB, 
either by decreasing PLB protein expression or by increasing PLB phosphorylation level. 
Ablation of PLB expression by genetic PLB knock-out or decrease PLB expression by 
RNAi resulted in improved contractility at cellular levels and suppressed progression of 
heart failure in animal models. [119,120,121] Expression of S16E-PLB, a 
phosphomimetic form, improved systolic and diastolic LV function in hamster, rat and 
sheep heart failing models. [122,123,124] Recent efforts to increase PLB phosphorylation 
level by inhibiting its dephosphorylation in heart failure models also showed promising 
results. This is done by introducing constitutively active truncated inhibitor-1, the 
inhibitor of protein phosphatase 1, which dephosphorylates PLB.[125,126,127,128,129] 
  
  15 
8BChapter 2 Fluorescence 
18B2.1 Fluorescence Theories 
Fluorescence is the emission of light from an excited singlet state to the ground 
singlet state. The concept of fluorescence is best described by a Jablonski diagram 
(Figure 6). The singlet ground, first, and second electronic states are depicted by S0, S1, 
and S2, respectively. Fluorophores at each of these electronic states can exist in a number 
of vibrational energy levels, depicted by 0, 1, and 2. At room temperature, thermal energy 
is not adequate to populate the excited vibrational states or the electronic state of S1. 
S0
S1
S2
Internal Conversion
kIC ~ 10
12 s-1
hνA
Absorption
kA ~ 10
15
Fluorescence
kF ~ 10
8 s-1
hνF
Non-radiative
Relaxation
kN ~ 10
8 s-1
0
1
2
 
Figure 6 Jablonski diagram. The fluorophore is excited to the higher energy state by absorption 
of a photon (hνA). Then it rapidly relaxes to the lowest vibrational state of S1. From there, the 
fluorophore returns to the ground state either through non-radiative relaxation, or by emission of 
a photon (hνF). 
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Therefore light is used to excite the fluorophore from the lowest vibrational state of S0 to 
some higher vibrational level of either S1 or S2. The transition time is about 10
-15
 s, too 
short for significant displacement of nuclei. This is the Franck-Condon principle. Then 
the fluorophores rapidly relax to the lowest vibrational level of S1, a process called 
internal conversion, with a rate of 10
12
 s
-1
 or higher. Fluorescence emission generally 
occurs quickly (kF ~ 10
8
 s
-1
) from the lowest vibrational state of S1 to different 
vibrational states of the ground state. The spacing of the vibrational energy levels of the 
excited states is similar to that of the ground state. Hence the emission spectrum is 
typically a mirror image of the absorption spectrum of the S0 to S1 transition. Figure 6 
also shows that the energy of emission is typically less than that of absorption, a 
phenomenon called Stokes shift. The excited fluorophore can either emit a photon at a 
rate of kF, or relax to the ground state non-radiatively at a rate of kN. The fluorescence 
quantum yield is the ratio of the number of photons emitted to the number absorbed. The 
fraction of fluorophores that decay through emission, and hence the quantum yield,   , is 
given by 
   
  
     
 Equation 1 
The lifetime of the excited state is defined by the average time the molecule spends in the 
excited state prior to return to the ground state. The lifetime is 
  
 
     
 
Equation 2 
 
Fluorescence measurements can be broadly classified into two types of 
measurements: steady-state and time-resolved. Steady-state measurements are performed 
with constant illumination and the intensity of emission spectrum is recorded. The 
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steady-state measurements can be easily done and for this reason it is the most common 
type. However, several key fluorophore parameters cannot be resolved by the steady-state 
method. For example, an ensemble of fluorophores with different lifetimes due to 
different environments cannot be resolved by steady-state fluorescence. Time-resolved 
fluorescence can resolve fluorophore ensembles, making it generally advantageous. 
Time-resolved measurements are done with pulsed excitation light, and the intensity 
decay is recorded on the nanosecond timescale. Suppose fluorophores are excited with an 
infinitely sharp pulse of light, resulting in an initial population (n0) of fluorophores in the 
excited states. If we use n(t) to denote the number of excited molecules at time t, then 
     
  
              Equation 3 
 
This results in an exponential decay of the excited state population 
                 Equation 4 
 
Because the fluorescence intensity I(t), which we observe in a fluorescence experiment, is 
proportional to n(t), then Equation 4 can be written as 
                 
Equation 5 
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19B2.2 Time-Correlated Single-Photon Counting (TCSPC) 
TCSPC is the most common method to 
measure time-resolved fluorescence. It is a 
sensitive technique for recording low-level light 
signals with picosecond resolution and high 
precision. The principle of TCSPC is shown in 
Figure 7. The sample is excited with a pulse of 
light, and the expected fluorescence decay 
waveform is shown at top. The time is measured 
between the excitation pulse and the observed 
photon (Figure 7 Middle) and stored in a 
histogram (Figure 7 Bottom). The conditions are 
adjusted so that less than 1 photon is detected per 
100 excitation pulses.  
 
Figure 7 Principle of fluorescence 
measurement by TCSPC. Figure taken 
from [130]. 
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The most common configuration of a TCSPC instrument is in the reversed  
start-stop configuration (Figure 8). After excitation of the fluorophores, the detector, 
photomultiplier tube (PMT), detects the arrival of the emitted photon and delivers a 
pulse. Then the pulse is fed to a constant fraction discriminator (CFD) to accurately mark 
the arrival time of the photon. The output of this CFD starts a time-to-amplitude 
converter (TAC), which generates a voltage ramp where the voltage increases linearly 
with time on the nanosecond timescale. A second CFD is used to obtain a timing 
reference pulse from the excitation pulse. The light in the reference channel is delayed by 
a defined time period by transmitted through a defined length of optic cable. The TAC is 
stopped by the output from the reference CFD. The TAC now contains a voltage in linear 
relationship with the arrival time of the emitted photon. The TAC output voltage is then 
amplified by a biased amplifier and then fed to the analog-to-digital converter (ADC). 
 
Figure 8 Reversed start-stop configuration of TCSPC. Figure taken from [130]. 
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This process is repeated numerous times to generate a histogram of the arrival time 
(Figure 7 Bottom). 
 
20B .3 Fluorescence Resonance Energy Transfer (FRET) 
FRET is a non-radiative transfer of energy from a donor fluorophore in the 
excited state to an acceptor molecule in the ground state (Figure 9). The emission 
spectrum of the donor fluorophore must overlap with the absorption spectrum of the 
acceptor molecule for FRET to occur. Energy is transferred through long-range  
dipole-dipole interactions, without the appearance of a photon. For this reason, the term 
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Figure 9 Schematic representation of FRET. Adapted from Dr. David Thomas’s lecture notes. 
Bottom: absorption (AbD) and emission (EmD) spectra of Alexa Fluor 350 as a donor, and the 
absorption (AbA) and emission (EmA) spectra of iodoacetamidofluorescein as an acceptor. 
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“Resonance Energy Transfer” or “Förster Resonance Energy Transfer” is sometimes 
preferred. 
The FRET efficiency (E) is the fraction of photons absorbed by the donor which 
are transferred to the acceptor. This fraction is given by 
  
     
  
        
 
Equation 6 
 
where τD is the lifetime of the donor in the absence of an acceptor, and kT(r) is the rate of 
energy transfer as a function of the donor-to-acceptor distance (r). In time-resolved FRET 
experiments, E is measured as the fractional decrease in lifetime: 
    
   
  
 Equation 7 
 
 
where    is the lifetime of the donor in the absence of an acceptor, and     is the lifetime 
of the donor which transfers energy to a nearby acceptor. The rate of energy transfer, 
kT(r), is given by 
      
 
  
 
  
 
   
Equation 8 
 
where R0 is the Förster distance, the distance at which FRET efficiency is 50%. [131]. 
Substituting into Equation 6, the FRET E can be directly expressed in terms of D-A 
distance r, 
  
  
 
  
    
 
Equation 9 
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The Förster distance (Å) is given by 
          
              
    Equation 10 
where κ2 is a factor describing the relative orientation in space of the transition dipoles of 
the donor and acceptor. κ2 is usually assumed to be equal to 2/3, which is appropriate for 
dynamic random averaging of the donor and acceptor. n is the refractive index of the 
medium. It is usually assumed to be 1.4 for biomolecules in aqueous solutions.    is the 
quantum yield of the donor in the absence of acceptor. J(λ) is the overlap integral which 
expresses the degree of spectral overlap between the donor emission and the acceptor 
absorption: 
     
∫            
   
 
 
∫        
 
 
 
Equation 11 
 
Förster distance falls in the range of 20 to 90 Å, which is comparable to the size 
of biomolecules. Hence FRET is frequently used to measure distances between two sites 
within a biomolecule or within a complex. For this reason, FRET is described as a 
“spectroscopic ruler”. [132] 
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21B3.1 Chapter Overview 
We have used membrane surface charge to modulate the structural dynamics of an 
integral membrane protein, phospholamban (PLB), and thereby its functional inhibition 
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of the sarcoplasmic reticulum Ca-ATPase (SERCA). It was previously shown by EPR, in 
vesicles of neutral lipids, that the PLB cytoplasmic domain is in equilibrium between an 
ordered T state and a dynamically disordered R state, and that phosphorylation of PLB 
increases the R state and relieves SERCA inhibition, suggesting that R is less inhibitory. 
Here we sought to control the T/R equilibrium by an alternative means – varying the lipid 
headgroup charge, thus perturbing the electrostatic interaction of PLB’s cationic 
cytoplasmic domain with the membrane surface. We resolved the T and R states not only 
by EPR in the absence of SERCA, but also by time-resolved fluorescence resonance 
energy transfer (TR-FRET) from SERCA to PLB, thus probing directly the SERCA-PLB 
complex. Compared to neutral lipids, anionic lipids increased both the T population and 
SERCA inhibition, while cationic lipids had the opposite effects. In contrast to 
conventional models, decreased inhibition was not accompanied by decreased binding. 
We conclude that PLB binds to SERCA in two distinct structural states of the 
cytoplasmic domain, an inhibitory T state that interacts strongly with the membrane 
surface, and a less inhibitory R state that interacts more strongly with the anionic SERCA 
cytoplasmic domain. Modulating membrane surface charge provides an effective way of 
investigating the correlation between structural dynamics and function of integral 
membrane proteins. 
 
22B3.2 Introduction 
The functions of integral membrane proteins depend on the interplay of protein 
structure and dynamics with the lipid environment [133]. In the present study, we use the 
lipid environment as a tool to perturb the system, followed by measurement of structure, 
dynamics, and function, to elucidate mechanistic principles. We vary membrane surface 
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electrostatics by manipulating lipid headgroup charge, which has been shown to be a 
powerful approach in the analysis of peripheral membrane proteins [134]. 
The sarcoplasmic reticulum Ca-ATPase (SERCA) actively transports Ca from the 
cytoplasm to the SR lumen and initiates muscle relaxation. In the cardiomyocyte, an 
integral membrane protein phospholamban (PLB) [135] regulates SERCA activity by 
decreasing SERCA’s apparent Ca affinity [136]. This inhibition can be relieved by 
elevated Ca
2+
 or by phosphorylation of PLB in response to -adrenergic stimulation 
[137]. Decreasing this inhibitory regulation relieves cardiomyopathy, so elucidating the 
interaction mechanism between SERCA and PLB is essential for understanding cardiac 
pathology and for devising new cardiac therapies [138]. 
PLB exists in equilibrium between monomeric and pentameric forms, but the 
monomer is the principle species that binds to and inhibits SERCA [139], so we used the 
monomeric AFA-PLB mutant (C36A/C41F/C46A) [28,78] throughout this study. The 
high-resolution structural dynamics of free PLB monomer in a lipid bilayer has been 
determined using nuclear magnetic resonance (NMR) and electron paramagnetic 
resonance (EPR) [28,78,83,140]. PLB consists of an N-terminal cytoplasmic helix, a 
loop, and a transmembrane helix (Figure 10). The top of the TM helix (domain Ib) is 
hydrophilic, directly interacts with lipid headgroups, and is more dynamic than the rest of 
the TM helix (domain II) [78,140,141]. EPR of TOAC, a spin label attached rigidly to the 
peptide backbone, shows that the cytoplasmic domain of PLB (Ia and Ib) is in 
equilibrium between an ordered T state and a dynamically disordered (partially unfolded) 
R state (sometimes called “excited state”), while the transmembrane helix is quite stable 
[78]. The cytoplasmic domain is associated with the membrane surface in T but 
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dissociated in R [78]. Phosphorylation of PLB induces a shift in the T/R equilibrium 
toward R, suggesting that R is less inhibitory than T [83,142]. 
Numerous high-resolution structures of SERCA in its enzymatic cycle have been 
obtained from X-ray diffraction [15,22], but there is no high-resolution structure of the 
SERCA-PLB complex. Based on crosslinking, mutagenesis and structures of free 
SERCA and free PLB, a docking model has been constructed, in which the cytoplasmic 
domain of PLB extends above the membrane surface and interacts with the cytoplasmic 
domain of SERCA [65]. Conventional models hypothesize that dissociation of this 
inhibitory SERCA-PLB complex is necessary for the relief of SERCA inhibition, either 
by high Ca, phosphorylation of PLB, mutagenesis of PLB, or addition of a PLB antibody 
[75,143], but EPR and NMR studies suggest that PLB remains bound to SERCA in both 
T (inhibitory) and R (less-inhibitory) states [69,83,144]. However, none of these 
spectroscopic studies probed specifically the bound SERCA-PLB complex. 
To help resolve this controversy, in the present study we have probed directly the 
structure of the SERCA-PLB complex, and we systematically tuned the structural 
dynamics of the cationic cytoplasmic domain of PLB by adjusting membrane surface 
charge using charged lipids. We first used EPR [83,145] of TOAC-PLB in the absence of 
SERCA, to show that we can control the T/R equilibrium using lipid headgroup charge. 
We then used time-resolved fluorescence resonance energy transfer (TR-FRET) [146] to 
directly measure SERCA-PLB binding and simultaneously resolve the T and R structural 
states of the SERCA-PLB complex (see section 3.6 for a brief introduction to FRET). We 
performed ATPase assays to determine the correlation of these observations with PLB 
inhibitory function. With this combined approach we constructed a revised model for the 
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structural and functional regulation of the SERCA-PLB complex. This approach has 
implications far beyond SERCA, demonstrating that variation of membrane surface 
electrostatics, in conjunction with high-resolution spectroscopy, is a potentially powerful 
approach to systematically tune the structural and functional dynamics of integral 
membrane proteins. 
 
23B .3 Results 
We used lipid headgroup charge as a means of perturbing electrostatically the 
structural equilibria of the SERCA-PLB system. The advantage of this approach is that it 
does not alter the native chemical compositions of the proteins, compared with 
conventional modifications such as mutagenesis, phosphorylation, and crosslinking. All 
lipids used have the same unsaturated fatty acid chains, di(C18:1), but varying 
headgroups and charges: phosphatidyl choline (PC, 0), phosphatidyl ethanolamine (PE, 
0), phosphatidyl glycerol (PG, −1), phosphatidyl serine (PS, −1), ethyl-phosphocholine 
(EPC, +1), and trimethyl-ammonium-propane (TAP, +1) (Figure 10). We hypothesized 
that the principal effect of this variation of membrane surface charge would be to perturb 
the equilibrium between the T state (membrane bound and highly ordered) and the R state 
(dissociated from the membrane and highly disordered). If our hypothesis is true,  
negatively charged lipids should increase the T state population and SERCA inhibition 
(Figure 10, top left), while positively charged lipids should have the opposite effects 
(Figure 10, top right). In this work, membranes were composed of PC, PE, and L at molar 
ratios 4/1/1, where L is PS, PG, PC, EPC, or TAP (Figure 10, bottom). PC and PE are in 
all samples, because they are the major constituent lipids in cardiac SR and are important 
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for SERCA activity and PLB-dependent regulation in reconstituted membranes 
[147,148]. The molar ratios of SERCA/PLB/lipid, when one or both proteins were 
present, were 1/10/700, which results in a functional regulation of SERCA by PLB that 
matches that in the native environment [85,149].  
EPR shows that the PLB structural distribution depends on lipid headgroup 
charge. We have previously shown that the TOAC spin label, rigidly coupled to the 
peptide backbone at position 11 on PLB, clearly resolves the T and R states [78,83,145]. 
Therefore, we used this EPR approach to determine the effect of lipid headgroup charge 
on the T/R equilibrium (Figure 11). The T state is dynamically restricted, resulting in a 
broad peak at lower field, while the dynamically disordered R state results in a sharp peak 
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Figure 10. Tuning the T/R equilibrium using lipid headgroup charge. Here and in subsequent 
figures, red indicates negative charge, blue positive. (a) The cationic cytoplasmic domain (Ia and 
Ib) of monomeric PLB is in equilibrium between an ordered T state and a dynamically disordered 
R state, while domain II is stable [78]. (b) Structures of lipid headgroups and their net charges. 
All lipids have the same fatty acid chain, X = C18:1 (oleic acid). 
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at higher field (Figure 11a). The positions and shapes of the two components did not 
change significantly with lipid headgroup charge, indicating that only the populations of 
the two states were affected. The mole fraction of PLB in the R state (XR) was determined 
by digital analysis of EPR spectra as described previously [145] (Figure 11b). XR is about 
0.20 in zwitterionic PC, while anionic PS and PG decrease XR substantially and cationic 
EPC and TAP increase XR (Figure 11). These results strongly support the hypothesis in 
Figure 10: the T/R equilibrium is influenced by the electrostatic interaction between the 
cationic cytoplasmic domain of PLB and the membrane surface charge; anionic lipid 
headgroups attract the cationic PLB cytoplasmic domain to the membrane surface, 
stabilizing the membrane-associated T state, while cationic lipid headgroups repel the 
cationic PLB cytoplasmic domain from the membrane surface, stabilizing the R state. 
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TR-FRET from SERCA to PLB resolves two structural states of the SERCA-
PLB complex. To further resolve the structure of the SERCA-PLB complex, we 
performed TR-FRET to measure the distance between IAEDANS-labeled SERCA 
(AEDANS-SERCA, donor) and Dabcyl-labeled PLB (Dabcyl-PLB, acceptor). The 
Förster distance (R0) between this pair is 3.2 nm [85]. IAEDANS labels SERCA 
specifically at Cys674, with the molar ratio of bound dye to SERCA = 1.02 ± 0.05 [150]. 
Synthetic AFA-PLB was labeled by attaching Fmoc-Lys(Dabcyl)-OH to the N-terminus 
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Figure 11. Effect of lipid headgroup charge on EPR of 11-TOAC spin-labeled PLB in lipid 
bilayers, with lipid composition and abbreviations as defined in Figure 10 (color scheme 
indicated in Figure 10b). (a) Low-field portion (3305 to 3341 G) of the spectrum resolves two 
distinct dynamic states of the PLB cytoplasmic domain, an ordered T state and a dynamically 
disordered R state. (b) Mole fraction of R state (XR). Mean  SEM (n = 3). Students t-test, 
compared with PC: * p < 0.05, ** p < 0.01. 
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at the last step of synthesis [149]. The time-resolved fluorescence of AEDANS-SERCA 
without (donor only, FD(t)) or with Dabcyl-AFA-PLB (donor plus acceptor, FD+A(t)) was 
measured by direct waveform recording using a high-performance time-resolved 
fluorescence instrument [151] (see section 3.5) (Figure 12a), then analyzed (Equation 
S14 - Equation S20) using non-linear fitting software. Conventional steady-state FRET 
only measures the ensemble-averaged interprobe distance. The principal advantage of 
TR-FRET is that it resolves directly the fraction Xb of the donor that has acceptor bound, 
thus reporting directly the structure of the SERCA-PLB complex (Equation S17 - 
Equation S20). Within this bound complex, TR-FRET also resolves multiple structural 
states, as defined by Gaussian interprobe distance distributions, each characterized by the 
center (Ri), width (FWHMi), and mole fraction (xi) (Equation S17 - Equation S20) 
[146,152]. For the bound complex in PC, two Gaussian components are necessary and 
sufficient to fit FDA(t) (Figure 12b, Figure S17). The shorter interprobe distance (R1) is 
1.75 ± 0.03 nm, with width FWHM1 = 0.99 ± 0.07 nm and mole fraction x1 = 0.77 ± 0.02. 
The longer interprobe distance (R2) is 3.03 ± 0.02 nm, with FWHM2 being 1.67 ± 0.24 
nm, and x2 = 1 - x1 = 0.23 ± 0.02. The fraction of SERCA bound to PLB (Equation S20), 
is Xb = 0.82 ± 0.01 in PC, indicating that 82% of SERCA is bound to PLB. These results 
support the model that the complex between SERCA and PLB is in equilibrium between 
two structural states (Figure 12), as is PLB in the absence of SERCA (Figure 11). 
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Ensemble average FRET shows that the average interprobe distance between 
SERCA and PLB is affected by lipid headgroup charge. Ensemble-average FRET 
efficiency ED+A (Figure 13a) was calculated using the average lifetime (Equation S16), 
which is equivalent to (but more precise than) FRET efficiency measured by fluorescence 
intensity under steady illumination [153]. Compared to zwitterionic PC, anionic PS and 
PG decreased FRET, suggesting an increase in the average interprobe distance, while 
cationic EPC and TAP increased the ensemble-average FRET, suggesting a decreased 
average interprobe distance (Figure 13a). These results suggest that the proximity 
between SERCA and PLB is affected by the electrostatic interaction between the lipid 
headgroup and the PLB cytoplasmic domain. However, this ensemble average 
measurement has no structural resolution, so it can not distinguish a change in binding 
from a change in the structure of the complex. Only TR-FRET can resolve the ambiguity. 
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Figure 12. TR-FRET from AEDANS-SERCA (donor) to Dabcyl-PLB (acceptor) in PC. (a) 
Example of TR fluorescence, measured by direct waveform recording in PC membranes. D = 
donor-only, D+A = donor plus acceptor. Gray = instrument response function (IRF). (b) SERCA-
PLB interprobe distance distribution determined from data in a, containing two Gaussian 
components (solid curve = sum of two dashed curves), centered at R1 and R2. (c) TR-FRET data 
resolves free SERCA (left, mole fraction 1-Xb) from PLB-bound SERCA-PLB (right, Xb). Two 
structural states of the bound SERCA-PLB complex are resolved (b), consistent with the model 
shown here. x1 and x2 are the mole fractions of the two states, corresponding to bound T and R 
states, as shown below. 
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Lipid headgroup charge modulates the distribution of the two structural 
states of the SERCA-PLB complex. TR-FRET waveforms were fitted as described in 
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Figure 13. Effects of lipid charge on SERCA-PLB structural distribution, determined from TR-
FRET. Two-Gaussian components distance distributions were determined as in Figure 12. 
Students t-test, compared with PC: * p < 0.05, ** p < 0.01. (a) Ensemble average FRET. (b) Mole 
fraction of SERCA bound to PLB. (c) Mole fraction of the short distance state (x1 = xR). (d) 
Centers R1 (open) and R2 (shaded) of the two distance distributions. (e) Widths.  
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Figure 12. In all cases, across the five different lipid compositions, two structural states 
were found to be necessary and sufficient to fit the data. The independently determined 
parameters (Figure 13b-e) were the fraction of SERCA bound to PLB (Xb) and mole 
fractions of bound states (x1 and x2) (Figure 12c), along with the structural characteristics 
of each bound state (R1, FWHM1, R2, FWHM2) (Equation S14 - Equation S20) (Figure 
12b). Membrane surface charge only slightly affects the binding (Xb) between SERCA 
and PLB (Figure 13b). In PS, PG and PC, Xb is ~ 0.8, while in EPC and TAP, Xb is ~ 0.9. 
Thus, most SERCA has PLB bound, and these small effects cannot explain the 
substantial dependence of ED+A on charge (Figure 13a). The two structural states have 
consistent properties, justifying their being treated as ‘states.’ The central interprobe 
distances of the two SERCA-PLB structural states were found to be quite invariant, with 
a short distance R1 ~ 1.8 nm, and a long distance R2 ~ 3.0 nm (Figure 13d). Some of the 
widths (FWHMi, defining the structural heterogeneity) of the distance distributions are 
slightly dependent on lipid headgroup charge (Figure 13e).  
The most prominent effect of membrane surface charge is to shift the equilibrium 
between the two structural states (Figure 13c). Compared to zwitterionic PC (x1 = 0.77 ± 
0.02), anionic PS and PG decrease x1 to 0.45 ± 0.10 and 0.49 ± 0.05 respectively. 
Cationic EPC and TAP increase x1 to 0.87 ± 0.02 and 0.87 ± 0.01 respectively. Thus in 
both isolated PLB (EPR in Figure 11) and in the SERCA-PLB complex (TR-FRET in 
Figure 13), the electrostatic interaction between the cytoplasmic domain of PLB and the 
membrane surface charge shifts the structural equilibrium between two structural states. 
Based on a comparison between EPR and TR-FRET data, it appears that population 1, the 
short distance state detected by TR-FRET, corresponds to the R state, while population 2 
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corresponds to the T state, as depicted in Figure 12c. Negative surface charge attracts the 
positively charged PLB cytoplasmic domain and thus increases the fraction (x2 = xT) of 
the membrane-associated bound T state (long interprobe distance), while positively 
charged headgroups have the opposite effect and thus increase the bound R state fraction 
(x1 = xR).  
SERCA activity in the absence of PLB depends on lipid headgroup charge. 
To establish control values, the ATPase activity of SERCA alone was measured at 
different pCa, and the pCa-dependence was fitted using Equation 12. There were no 
significant effects on the Vmax (activity at saturating Ca), but there were significant effects 
of headgroup charge on pKCa, defining the apparent Ca affinity (Table 1). Compared to 
PC (zwitterionic), PS and PG (anionic) increase pKCa, while EPC and TAP (cationic) 
decrease it. 
 
 
 
Table 1. Lipid charge effects on SERCA activity 
(Equation 12). (Mean  SEM. n  4) 
Lipid 
(charge) 
pKCa Vmax  
PS (-) 6.81  0.01 1.65  0.03 
PG (-) 6.73  0.02 1.55 ± 0.12 
PC (0) 6.68  0.02  1.65  0.19 
EPC (+) 6.53  0.03 1.46 ± 0.10 
TAP (+) 6.51  0.02 1.66  0.19 
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Lipid headgroup charge affects SERCA inhibition by PLB. The inhibitory 
function of PLB is defined by its shift of the apparent SERCA Ca affinity, ΔpKCa (Figure 
14a, Equation 13). In order to compare the inhibitory potency of PLB in various lipid 
environments, pKCa was normalized to the value obtained with PC (Figure 14b). The 
results show that PLB is more inhibitory in the presence of anionic lipids PS and PG, and 
less inhibitory in the presence of cationic lipids EPC and TAP. Previous results showed 
that PLB phosphorylation, which decreases inhibition of SERCA, increases the 
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Figure 14 Effects of lipid headgroup charge on SERCA inhibition. (a) Activity of SERCA in PC 
without (■) and with (▲) AFA-PLB. Solid curves are the best fit using Equation 12. Error bars 
are SEM (n = 4). (b) Inhibitory potency, defined as pKCa normalized to the value for PC (mean  
SEM. n = 4-6).  Students t-test, compared with PC: * P < 0.05, ** P < 0.01. 
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population in the dynamically disordered R state [83]. The results of Figure 14b show 
that membrane surface charge modulates PLB’s effect on SERCA by an analogous 
mechanism, confirming the conclusion above that the R state corresponds to the 
structural state having the shorter interprobe distance (population 1 in Figure 12 and 
Figure 13). 
 
24B3.4 Discussion 
Bimodal structure of the SERCA-PLB complex resolved by TR-FRET. Using 
EPR, we demonstrated that anionic lipids attract the cationic cytoplasmic domain of PLB 
to the membrane surface and thus increase the population of the membrane-associated T 
state, while cationic lipids do the opposite, increasing the R state population (Figure 11). 
We then used TR-FRET to resolve two distinct structural states of the bound SERCA-
PLB complex (Figure 13) and observed a similar effect, with the R state assigned to the 
population having the shorter interprobe distance (Figure 13). Membrane surface charge 
shifts the equilibrium between the T/R states with little or no effect on the two structural 
states themselves (Figure 13d). This supports a model in which the cytoplasmic domain 
of the SERCA-bound T state is membrane associated, while that of the SERCA-bound R 
state loses contact with the membrane surface and contacts the SERCA cytoplasmic 
domain (Figure 12c). 
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Mechanism of SERCA regulation. As we systematically varied the membrane 
surface charge, we observed a strong correlation between the population of the R state 
and PLB inhibitory function (Figure 15a). This finding is consistent with previous results 
showing that phosphorylation of PLB, which decreases SERCA inhibition, also increases 
xR [83], as do some loss-of-inhibition mutations in PLB [154]. In the current study, we 
show that varying the membrane surface charge serves not only to relieve inhibition 
(positive charge increases xR), but also to increase inhibition (negative charge decreases 
xR). Thus we obtain convincing evidence that this correlation between structural 
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Figure 15. Correlation of inhibitory potency with the T/R equilibrium. (a) As the fraction of 
SERCA-PLB complex in the R state (xR) increases, in response to increasing membrane surface 
charge, the inhibitory potency of PLB (defined in Figure 14) decreases. (b) Model consistent with 
the data. Both T and R states bind to SERCA. The membrane-associated T state is more inhibitory 
than the extended R state. Negative surface charge shifts the equilibrium toward T, increasing 
inhibition (top), while positive surface charge does the opposite (bottom). 
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dynamics and function holds even in the absence of PLB covalent modification (e.g., 
phosphorylation or mutation): it is primarily the T/R equilibrium that determines SERCA 
function (Figure 15b). 
Structural dynamics, not SERCA affinity, determines the inhibitory potency 
of PLB. TR-FRET clearly resolves free SERCA from the bound SERCA-PLB complex 
(Figure 12c), and shows that relief of inhibition does not arise from a change in Xb, the 
fraction of SERCA bound to PLB (Figure 13b).  In both neutral (PC) or anionic lipids 
(PS, PG) (Figure 13b), 80% of the SERCA is bound to PLB (Xb ~ 0.8), but PLB is more 
inhibitory in anionic lipids (Figure 14b). Cationic lipids (EPC and TAP) actually increase 
slightly the fraction of SERCA bound to PLB (Xb ~ 0.9, Figure 13b), but PLB inhibitory 
function decreases (Figure 14b). This is opposite from the effect expected if relief of 
inhibition were due to dissociation of the complex. Therefore, the functional effects are 
due to structural changes within the bound SERCA-PLB complex (Figure 15b), not to 
changes in SERCA-PLB affinity. It has been shown that the transmembrane helix of PLB 
without the cytoplasmic domain is sufficient to inhibit SERCA activity [60], so the role 
of the cytoplasmic domain is to relieve this inhibition when it is in the R state. Future 
studies must investigate how the dynamic disorder of the R state propagates allosterically 
to the transmembrane domain, interrupting the inhibitory interaction of the 
transmembrane domain with SERCA. This will have important implications for 
therapeutic engineering in this system, since it offers the hope of designing mutant 
proteins or drugs that stabilize the non-inhibitory R state and thus relieve SERCA 
inhibition, without the need to dissociate PLB from SERCA [149,154].  
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Relationship to previous work. The fraction xR is much greater when PLB is 
bound to SERCA (Figure 12, Figure 13c) than when it is free (Figure 11); this is 
consistent with previous studies by EPR [83,144] and crosslinking [65], all of which 
suggest that SERCA decreases PLB’s interaction with the membrane surface. This is 
presumably due in part to the negative charge of the SERCA cytoplasmic domain 
(indicated by red color in Figure 12c and Figure 15b), which attracts the positively 
charged PLB cytoplasmic domain. Thus a negatively charged membrane surface 
competes most effectively for PLB binding (Figure 13c). Previous NMR results 
suggested that several residues around Lys3 on PLB are in contact with SERCA [69]. 
NMR also provides more detailed structural insight into the interactions between PLB 
and the membrane surface, involving both hydrophobic and hydrophilic side chains 
[81,155]. Previous NMR results showed that the anionic PG increases the population of 
the restricted T state of PLB in the absence of SERCA [81], consistent with the EPR 
results here (Figure 11).  
Implications for SERCA regulation in native SR. The primary purpose of our 
manipulation of the lipid environment in this study was to perturb the structural and 
functional dynamics of SERCA-PLB through a mechanism distinct from PLB 
phosphorylation. However, it is also important to ask how these results relate to 
conditions in native cardiac SR. Our lipid headgroup composition is similar to that of 
cardiac SR, where PC is predominant (53%), followed by PE (27%) and PS (10%) [156]. 
However, most (76%) of the negatively charged PS headgroups face the lumen [156], so 
it is unlikely that they interact significantly with the cytosolic domain of PLB. Thus, 
since virtually all of the lipids facing the cytosol are neutral, it is likely that the conditions 
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in cardiac SR are best mimicked by our sample in which all lipids are neutral, where 77% 
of the SERCA-PLB complex is in the less inhibitory R state (Figure 15a). These results 
suggest that in cardiac SR, a minor population of PLB in the T state is enough to inhibit 
SERCA substantially. At first glance, this seems surprising, but it means that 
phosphorylation of PLB need only shift about 23% of PLB to the R state to maximally 
activate SERCA. This is analogous to the poised equilibrium in the regulatory light chain 
of smooth muscle myosin, where phosphorylation causes just a 22% shift in the dynamic 
structural equilibrium but results in profound activation [146]. 
Lipid headgroup charge as a research tool to tune the structural and 
functional dynamics of integral membrane proteins. It has been an effective strategy 
to vary the physical properties of the hydrophobic core of the membrane, such as the 
hydrophobic thickness and fluidity [157,158], to investigate the structural and functional 
dynamics of integral membrane proteins. The composition of lipid headgroups is also 
critical for the function of membrane proteins [134], including SERCA [147,159]. 
Researchers have varied the zwitterionic and anionic lipid compositions to mimic native 
membrane environments [160,161]. Cationic lipids, on the other hand, do not occur 
naturally and have been used primarily as tools in liposomal transfection [162] and lipid 
transfer [163]. The present study introduces them as agents to perturb the structure and 
function of membrane proteins. Using lipids with anionic, zwitterionic, and cationic 
headgroups, we controlled the surface electrostatics and tuned successfully the structural 
dynamics of an integral membrane protein complex. Compared to altering the protein 
structure through direct chemical modifications such as mutagenesis, phosphorylation, 
lipidation, methylation, and crosslinking, this method preserves the chemical integrity of 
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the proteins involved. Although the present study focuses on charge variation, it is clear 
from the data that charge is not the only headgroup property that affects structural 
dynamics and function in the SERCA-PLB system – the two anionic lipids do not cause 
identical effects; neither do the two cationic lipids. Nevertheless, despite substantial 
variation in headgroup size and shape, the correlations of structure and function with 
charge are clear (Figure 15). 
25B3.5 Materials and Methods 
Sample preparation and assays. SERCA was purified from rabbit skeletal 
muscle using reactive red in 0.1% octaethylene glycol monododecyl ether (C12E8) [85]. 
Purified SERCA was labeled with AEDANS as previously described [85] and flash 
frozen in sucrose buffer (300 mM sucrose, 20 mM 3-(N-morpholino) propanesulfonic 
acid (MOPS), pH 7.0, 4 °C). The dye-to-protein ratio was determined by measuring the 
absorbance at 334 nm (ε = 6100 M-1 cm-1) in a denaturing buffer (0.1 M NaOH, 1% 
sodium dodecyl sulfate). Solid-phase peptide synthesis and HPLC purification were used 
to prepare AFA-PLB, as previously reported [78,83]. Fluorescence Labeling at the N-
terminus was accomplished by incorporation of Fmoc-Lys(Dabcyl)-OH during peptide 
synthesis. Fmoc-TOAC-OH (2,2,6,6-tetramethylpiperidine-1oxyl-4-amino-4-carboxylic 
acid) was incorporated in the AFA-PLB sequence at position 11, as previously reported 
[164]. Characterization was accomplished by mass spectrometry (MALDI-TOF) and 
Edman protein sequencing. PLB concentrations were measured with the BCA assay 
(Pierce) and by amino acid analysis. Functional reconstitution of SERCA and/or PLB 
was performed as described previously [35,83], adapted for systematic variation of lipid 
composition. The final molar ratio of SERCA/PLB/lipid was 1/10/700, with either one or 
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both proteins present. The molar lipid composition was PC/PE/L = 4/1/1, where L = PS 
(−), PG (−), PC (0), EPC (+) and TAP (+). 
Ca-ATPase activity was measured at 25 °C as a function of pCa using an enzyme-
linked ATPase assay in a microplate reader [85]. The data were fitted by 
   
    
                
 Equation 12 
where Vmax is the maximum ATPase rate, pKCa is the apparent Ca affinity, and n is the 
Hill coefficient. The inhibitory potency of PLB was defined as the decrease in the 
apparent Ca
2+
 affinity of SERCA: 
                             Equation 13 
EPR spectroscopy. EPR spectra were acquired with a Bruker EleXsys E500 
spectrometer equipped with a 4122 SHQ cavity. A quartz dewar and Bruker N2 
temperature controller were used to maintain the samples at 25 ± 0.1 °C. Spectra were 
acquired using 12.6 mW microwave power, 100 kHz modulation frequency with 1 G 
peak-to-peak amplitude, and a 120 G sweep width. Mole fractions of populations, 
resolved by rotational dynamics, were determined by fitting the spectra to numerical 
simulations [83]. 
FRET spectroscopy. Fluorescence waveforms were acquired using a high-
performance time-resolved fluorescence (HPTRF) spectrometer constructed in this 
laboratory [151], which uses direct waveform recording (DWR) rather than the 
conventional method of time-correlated single-photon counting (TCSPC). As shown 
previously, when identical samples are studied, this DWR instrument offers 105 times 
higher throughput than TCSPC, while providing at least comparable performance in 
signal/noise, accuracy, and resolution of distinct components [151]. AEDANS-SERCA 
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was excited using a passively Q-switched microchip YAG laser (NanoUV-355; JDS 
Uniphase), at 355 nm with a pulse repetition frequency of 10 kHz. The high energy (1 mJ 
/ pulse) narrow (~ 1 ns full width at half maximum) laser pulses are highly uniform in 
shape and intensity. Emitted photons pass through a polarizer set to the magic angle 
(54.7°), followed by an interference bandpass filter (Semrock 470/22 nm), detection with 
a photomultiplier tube (PMT) module (H5773-20, Hamamatsu), and digitization (Acqiris 
DC252, time resolution 0.125 ns). TR-FRET waveforms were analyzed as described 
previously [146] and described in SI. For all FRET samples analyzed, two Gaussian 
distance distributions were necessary and sufficient to fit the data (Figure S17). 
 
26B3.6 Supplementary Information 
TR-FRET data analysis. Fluorescence waveforms were analyzed using a non-
linear least-squares fitting as described previously [146,165]. The observed donor-only 
waveform FDobs(t) was fitted by a simulation FDsim(t), consisting of a multiexponential 
decay FD(t) convolved with the instrument response function IRF(t) (Figure 12a, acquired 
from light scattering). 
 
FD(t) = 

n
i 1
Ai exp(-t/Di) , 
FDsim(t) = 


IRF(t-t) FD(t) dt, 
Equation S14 
where Di are the donor-only fluorescence lifetimes. The ensemble-average lifetime is 
given by: 
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 D = 

n
i 1
Ai  Di / 

n
i 1
Ai Equation S15 
The observed donor + acceptor waveform FD+Aobs(t) was sometimes fitted to a 
multiexponential function using the same approach. The ensemble-average FRET 
efficiency, which is equivalent to the result of a steady-state fluorescence measurement 
[153], is given by:  
 ED+A  = 1 – D+A / D . Equation S16 
To resolve structural states, a distribution of donor-acceptor distances (r) was 
assumed:  
 FDA(t) =   




n
i
R
1
 Ai exp[(-t/ Di)(1+[R0i/R]
6
)]dR, Equation S17 
where R0i is the lifetime-weighted Förster distance [146] (in Å): 
 R0i
6 
= 9780
6
J2 n-4kradDi Equation S18 
where J is the overlap integral between the donor emission and acceptor absorption 
spectra, n is the refractive index (1.4), 2 is the orientation factor (2/3, assuming random 
orientation), and krad is the radiative decay rate for the donor. The value of krad, which is 
assumed to be invariant for each donor, is the ratio of the quantum yield QD over the 
average lifetime of the donor  D (Equation S15) and was measured previously to be 
0.0257 ns
-1
 for AEDANS
 
[146]. Equation S18 follows directly from the Förster theory’s 
assumption [131,146] that the energy transfer rate constant kT (= R0i
6
R
-6
/ Di) depends on 
the donor-acceptor distance R but not on the donor-only lifetime Di. Here we also 
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assume that the orientation factor 2 does not change from one structural state to another, 
but this is justified by low fluorescence anisotropy values that were observed. R0 between 
AEDANS-SERCA and Dabcyl-PLB is 3.2 nm [85].  
The distance distribution (r) (Equation S17) was assumed to be a sum of n 
Gaussian components, each corresponding to a structural state of the SERCA-PLB 
complex, with its central distances Rj, widths FWHMj, and mole fractions xj  
The observed waveform FD+Aobs(t) was fitted by FD+Asim(t): 
 
FD+A(t) = (1 – Xb)FD(t) + XbFDA(t),  
      tdtFttIRFtF
ADAsimD




  ,  
Equation S20 
where Xb is the fraction of donor-labeled SERCA bound to and transferring energy to 
acceptor-labeled PLB. Thus binding (Xb) is determined independently of the mole 
fractions of resolved structural states (xj in Equation S19). 
Donor-only fluorescence decays are best fit with 3 exponential components. 
The donor-only fluorescence decay FD(t) (Figure S16a), was fitted with a 
multiexponential function (Equation S14), with the result that three lifetime components 
are necessary and sufficient to fit the data (Equation S14, n = 3), based on the residual 
(R) = 

n
j 1
 x j j
-1
(2π)-1/2 exp(-[(R-Rj)/(2j)]
2
, 
j = FWHMj/[2*(2 ln 2)
1/2
], 


n
j 1
 x j = 1 
Equation S19 
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plots (data – fit, Figure S16b) and the 2 values (sum of residuals at each data point, 
Figure S16c). The results show clearly that the fit is improved by increasing n from 2 to 
3, but not by increasing n from 3 to 4. The fitting results are summarized in Table S2. 
The donor-only fluorescence lifetime is not sensitive to the lipid environment (Table S3), 
presumably because the labeling site (Cys674) is elevated far from the membrane 
surface. Therefore, to increase precision in the FRET analysis, the three donor lifetime 
values were globally linked. The corresponding R0i (Equation S18) values are listed in 
Table S3.  
 
 
 
Table S2. Fluorescence lifetime of AEDANS-SERCA in charged lipid vesicles, analyzed using 
Equation S14 and Equation S15 (mean  SEM, N= 4). 
Lipid 
(charge) 
A1 τ1 A2 τ 2 A3 τ 3 〈 τ 〉 
PS (-) 
0.418  
0.016 
0.112  
0.009 
0.055  
0.004 
4.96  
0.85 
0.527  
0.018 
18.9  
0.1 
10.3  
0.3 
PG (-) 
0.412  
0.015 
0.134  
0.017 
0.055  
0.003 
5.36  
0.46 
0.532  
0.015 
18.9  
0.1 
10.4  
0.3 
PC (0) 
0.403  
0.009 
0.13  
0.013 
0.054  
0.001 
5.27  
0.39 
0.544  
0.009 
18.9  
0.1 
10.6  
0.2 
EPC (+) 
0.415  
0.01 
0.124  
0.01 
0.059  
0.002 
4.88  
0.53 
0.526  
0.011 
18.8  
0.1 
10.2  
0.2 
TAP (+) 
0.392  
0.013 
0.134  
0.002 
0.056  
0.003 
4.37  
0.42 
0.551  
0.01 
18.8  
0.1 
10.7  
0.2 
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Figure S16. Fluorescence lifetime fit of IAEDANS-labeled SERCA. (a) Fluorescence data, fit 
and instrument respond function. (b) normalized residual plots ((data – fit) / max fit value) of fits 
with increasing number of lifetime components (Equation S14, n = 1-4). 
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Table S3. The three fluorescence lifetimes of AEDANS-SERCA were globally linked for all 
samples, and the three R0i values were calculated using Equation S19 (mean  SEM, N= 4). 
 Ai τi R0i 
1 0.407  0.09 0.122  0.012 15.2  0.3 
2 0.052  0.001 4.32  0.25 27.6  0.2 
3 0.541  0.01 18.7  0.1 35.3  0.1 
 
 
 
Two structural states are necessary and sufficient to fit the TR-FRET data. 
To resolve structural states within the SERCA-PLB complex, we used FD(t) as input 
(Table S3), to fit FD+Aobs(t) and determine the interprobe distance distribution (Equation 
S17 – Equation S20). We tested models with one, two, and three Gaussian components 
(Equation S19, n = 1, 2, and 3). The goodness of fit was evaluated to minimize 2 (Figure 
S17). The fit was consistently improved by increasing the distance components (n in 
Equation S19) from 1 to 2, but not from 2 to 3 (Figure S17). Thus two Gaussian distance 
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Figure S17. Time-resolved FRET resolves two structural states of the SERCA-PLB complex in 
zwitterionic lipid vesicles. Examples of the fluorescence waveforms of AEDANS-SERCA only 
(D) or co-reconstituted with Dabcyl-AFA (D+A) are in (Figure 12a). The instrument-response 
function (IRF in Figure 12a) was convolved with simulated decays (Equation S17 - Equation 
S20), then fitted to the experimental waveforms. (a) normalized residual plots show that 2G 
(Equation S19, n = 2) is better than 1G, while 3G doesn’t improve the fit. (b) The 2 values 
confirm that the 2G model is necessary and sufficient to fit the data.  
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distributions are necessary and sufficient to fit the TR-FRET data, and we conclude that 
the SERCA-PLB complex adopts two distinct structural states. The results are 
summarized in Figure 12 and Figure 13. We also fit the data with a model-independent 
multiexponential function as in Equation S14, and found that a three-exponential function 
(Equation S14, n = 3) gave as good a fit as the double-Gaussian (Equation S19, n = 2).  
However, this fit did not allow us to quantitate binding from structural changes, nor did it 
provide a realistic physical view of this dynamic protein complex. This same two-
Gaussian analysis was successfully applied previously to similar FRET data from smooth 
muscle myosin regulatory light chain [146] and the myosin relay helix [152], generating 
high-resolution structural information that was confirmed by independent molecular 
dynamics simulations [146] or by dipolar electron–electron resonance (DEER) EPR 
spectroscopy [152]. 
 
Support-Plane Analysis. We analyzed the 2 surface to estimate the uncertainty 
of the fitting parameters (Figure S18). To generate the 2 surface, the parameter of 
interest is fixed (x-axis), and all other parameters are allowed to vary to minimize 2 (y-
axis). The red bar represents 67% confidence level. Thus the uncertainties are ± 0.01 nm 
for R1 and R2, ± 0.015 nm for FWHM1, and ± 0.075 nm for FWHM2.  These uncertainties 
were typically comparable to or less than those obtained from the standard deviations of 
multiple experiments (Figure 13). Uncertainties in widths FWHMi are typically greater 
than those of the center distances Ri (Figure S18), and the same trend is seen in the error 
bars (SEM values) from multiple experiments (Figure 13). 
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1.79 nm 1.81 nm 1.25 nm 1.28 nm
R1 FWHM1
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3.32 nm 3.34 nm 2.33 nm 2.48 nm  
Figure S18. Uncertainty of fitting parameters estimated by χ2 surface (“support-plane”) analysis. 
This example is in PS vesicles. The intersection between the horizontal red line and the blue χ2 
surface represents 67% confidence level.  
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27B4.1 Chapter Overview 
We have used time-resolved fluorescence resonance energy transfer (TR-FRET) 
to characterize the interaction between phospholamban (PLB) and the sarcoplasmic 
reticulum (SR) Ca-ATPase (SERCA) under conditions that relieve SERCA inhibition. 
Unphosphorylated PLB inhibits SERCA in cardiac SR, but inhibition is relieved by either 
micromolar Ca
2+
 or PLB phosphorylation. In both cases, it has been proposed that 
inhibition is relieved by dissociation of the complex. To test this hypothesis, we attached 
fluorophores to the cytoplasmic domains of SERCA and PLB, and reconstituted them 
functionally in lipid bilayers. TR-FRET, which permitted simultaneous measurement of 
SERCA-PLB binding and structure, was measured as a function of PLB phosphorylation 
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and [Ca
2+
]. In all cases, two structural states of the SERCA-PLB complex were resolved, 
probably corresponding to the previously described T and R structural states of the PLB 
cytoplasmic domain. Phosphorylation of PLB at S16 completely relieved inhibition, 
partially dissociated the SERCA-PLB complex, and shifted the T/R equilibrium within 
the bound complex toward the R state. Since the PLB concentration in cardiac SR is at 
least 10 times that in our FRET measurements, we calculate that most of SERCA 
contains bound phosphorylated PLB in cardiac SR, even after complete phosphorylation. 
4 M Ca2+ completely relieved inhibition but did not induce a detectable change in 
SERCA-PLB binding or cytoplasmic domain structure, suggesting a mechanism 
involving structural changes in SERCA’s transmembrane domain. We conclude that Ca2+ 
and PLB phosphorylation relieve SERCA-PLB inhibition by distinct mechanisms, but 
both are achieved primarily by structural changes within the SERCA-PLB complex, not 
by dissociation of that complex. 
 
 4.2 Introduction 
A hallmark of heart failure is dysregulation of intracellular Ca
2+ 
handling [99], 
primarily caused by inadequate removal of Ca
2+
 from the cytosol by the 
sarco(endo)plasmic reticulum Ca
2+
-ATPase (SERCA) [166], which actively sequesters 
Ca
2+
 back into the sarcoplasmic reticulum (SR) at a ratio of 2 Ca
2+
 per ATP hydrolyzed 
[167]. In the heart, SERCA is regulated by phospholamban (PLB), a single-pass integral 
membrane protein. Unphosphorylated PLB inhibits SERCA by decreasing its apparent 
Ca
2+
 affinity [136]. Under physiological conditions, this inhibition is relieved by either 
micromolar Ca
2+
 or by phosphorylation of PLB, primarily by protein kinase A (PKA) at 
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S16 [168]. Recent gene therapies targeting increased SERCA activity show promise for 
alleviation of heart failure [169]. Ablation of PLB or introduction of phosphomimetic 
mutant S16E-PLB suppress progression of heart failure in animal models [120,123,124]. 
Overexpression of SERCA2a, the cardiac isoform, has successfully completed Phase IIa 
clinical trials [170]. These studies validate the SERCA-PLB complex as a potent 
therapeutic target for heart failure. However, rational design of improved therapies is 
hampered by uncertainty regarding the mechanism by which PLB regulates SERCA. 
Two structural mechanisms for relief of SERCA inhibition have been proposed. 
The dissociation model hypothesizes that PLB dissociates from SERCA to relieve 
inhibition. This model is supported by crosslinking and co-immunoprecipitation studies 
that found decreased physical interaction between SERCA and PLB at either micromolar 
Ca
2+
 or after phosphorylation at S16 by PKA [54,72,73,74,75,76]. However, recent 
spectroscopic studies support the subunit model, in which inhibition of SERCA is 
relieved by structural rearrangements within the SERCA-PLB complex, not by 
dissociation. Electron paramagnetic resonance (EPR) and fluorescence resonance energy 
transfer (FRET) studies showed that PLB remains bound to SERCA when the pump is 
activated [85,86,171,172]. EPR and NMR studies showed that the cytoplasmic domain of 
PLB exists in equilibrium between a T state that is ordered and an R state that is 
dynamically disordered [78,80,145]. Phosphorylation shifts the equilibrium toward the R 
state and relieves inhibition [83]. FRET studies showed that variation of lipid headgroup 
charge shows a strong correlation between the population of the R state and SERCA-PLB 
activation, without dissociation, further validating the subunit model [84]. That study 
showed the power of time-resolved (TR) FRET to distinguish between changes in 
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structure and association. In the present study, we have used TR-FRET, using 
fluorophore-labeled SERCA and PLB reconstituted in lipid bilayers, to resolve the effects 
of both micromolar Ca
2+ 
and PLB phosphorylation on the structure and stability of the 
SERCA-PLB complex. These results provide definitive insights into the molecular 
mechanisms underlying relief of inhibition in cardiac SR. 
 
29B4.3 Materials and Methods 
SERCA purification and labeling 
Crude SR vesicles were prepared from the fast-twitch skeletal muscle of New 
Zealand white rabbits [173]. SERCA was further purified from crude SR vesicles using 
reactive-red chromatography [174]. For FRET studies, purified SERCA was labeled with 
5-iodoacetamidofluorescein (IAF) (Invitrogen, CA) specifically and completely at C674 
[175].  
 
Expression, purification, phosphorylation and labeling of PLB 
Native PLB equilibrates between monomers and homopentamers [139]. To 
simplify the analysis and focus on the SERCA-PLB interaction, a monomeric mutant of 
PLB was used, with the three cysteine residues (C36, C41 and C46) in the 
transmembrane domain mutated to alanine, phenylalanine, and alanine, respectively 
[176]. Site-directed mutagenesis was performed to mutate Y6 to C for thiol-reactive 
fluorophore attachment. This site was chosen because Y6 is not involved in the 
interaction with SERCA [69]. Recombinant PLB was expressed in E. coli and purified as 
previously published [177]. For site-directed fluorophore labeling, lyophilized PLB 
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powder was dissolved at a concentration of 0.2 mM in 20 mM MOPS, 1% octyl -D-
glucopyranoside (OG), pH 7.0. Alexa Fluor® 350 C5 maleimide (Invitrogen, CA) freshly 
dissolved in DMSO was then added at 10-fold molar excess. The reaction was allowed to 
proceed at room temperature for 1 hour, and the labeled PLB was purified by reversed-
phase HPLC. For phosphorylation studies, labeled PLB was phosphorylated as described 
previously [139] and purified by reversed-phase HPLC. Complete labeling and 
phosphorylation of PLB was confirmed by ESI-MS. The concentration of PLB was 
measured by the BCA assay. 
 
Co-reconstitution of SERCA and PLB 
SERCA and PLB were co-reconstituted into lipid vesicles using 4:1 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC)/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) (mol/mol) to yield unilamellar vesicles [148]. Ca
2+
-ATPase activity and FRET 
measurements were performed immediately after co-reconstitution. The final buffer 
composition of FRET samples was 50 mM MOPS, 50 mM KCl, 5 mM MgCl2, 1 mM 
EGTA, pH 7.0, with varying concentrations of CaCl2 to yield the desired free Ca
2+
 
concentration (pCa 8.0, 6.4, or 5.4). 
 
Ca
2+
-ATPase functional measurements 
To ensure that labeled SERCA and PLB remain functional, we measured the 
ATPase activity of co-reconstituted samples at 25
o
 C, using an NADH-linked enzyme-
coupled assay [148,149]. The Ca
2+
-dependent rate of ATP consumption was fitted to the 
Hill equation,  
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V = Vmax/[1+ 10
–n (pKCa – pCa)
],  Equation 21 
where pCa = -log10 [Ca
2+
], Vmax is the limiting activity at saturating calcium, pKCa is the 
pCa value where V = 0.5Vmax, and n is the Hill coefficient. The inhibition of SERCA by 
PLB is shown as ΔpKCa, the shift of pKCa upon addition of PLB.  
 
Time-resolved fluorescence resonance energy transfer (TR-FRET) measurements 
SERCA and PLB were labeled with fluorophores at the sites shown in Figure 
19A. PLB was labeled with Alexa Fluor 350 maleimide (donor) at Y6C, and SERCA was 
labeled with IAF (acceptor) at C674. The quantum yield of bound Alexa Fluor 350 
maleimide was measured in 20 mM MOPS, 1% OG, pH 7.0, using quinine sulfate 
dehydrate (AnaSpec, CA) as the standard, yielding a quantum yield of 0.48 for PLB, 0.80 
for phosphorylated PLB (pPLB). The corresponding R0 values [178] are calculated to be 
4.6 nm and 5.0 nm, respectively. The time-resolved fluorescence decay of co-
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Figure 19: TR-FRET experimental design. A Models of SERCA-PLB complex. SERCA (silver)-
bound PLB (blue) is proposed to exist in an equilibrium between T and R states, as shown 
previously by EPR [83]. There is no high-resolution structure of the SERCA-PLB complex, but a 
model for the R state (right) is from [65], and the T state model (left) is based on the NMR 
structure of PLB. The labeling sites on SERCA (C674) and PLB (Y6C) are shown as green and 
magenta spheres, respectively. The interprobe distances in T and R states are denoted as r
T
 and r
R
, 
respectively. Image created in VMD [14]. B Representative fluorescence waveforms. D. donor 
only. D+A, donor plus acceptor. Grey indicates instrument response function. C Interprobe 
distance distributions resolved from fluorescence waveforms in B. Two Gaussian distance 
distributions were resolved. The shorter and longer distances correspond to R and T states, 
respectively [84]. 
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reconstituted samples was measured by time-correlated single-photon counting (Becker-
Hickl, Berlin, Germany), following excitation at 385 nm using a subnanosecond pulsed 
diode laser (PicoQuant, Berlin, Germany), filtering the emitted light using a 440/40 filter 
(Semrock, NY), and detection with a PMH-100 photomultiplier (Becker-Hickl). The 
instrument response function (IRF, Figure 19B) was recorded from water. TR-FRET data 
was analyzed as previously published [84]. The observed donor-only waveform (Figure 
19B) was fitted by a simulation FDsim(t), consisting of a multi-exponential decay FD(t) 
convoluted with the IRF 

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
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Equation 22 
where 
Di
 is the fluorescence lifetime of the ith component. In this study, two 
exponentials were sufficient to fit the donor-only waveform (Figure S23). The waveform 
of the samples containing donor and acceptor (Figure 19B), was fitted by FD+A,sim(t):  
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where x
DA
 is the mole fraction of donor-labeled PLB that is bound to acceptor-labeled 
SERCA, and FDA,j(t) is the fluorescence waveform of the jth donor-acceptor complex. We 
found that m=2 was sufficient (Figure S25).  
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where Roi is the Förster distance of Alexa Fluor 350 and IAF, and (R) is the distance 
distribution function, assumed to be sum of Gaussians, each with a mole fraction xj, a 
center rj and a full width at half maximum (FWHMj) (Figure 19C): 
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We assumed that PLB and pPLB populate the same two states, because the 
distance parameters resolved from independent fittings are similar for PLB and pPLB 
(Figure S24) and this assumption does not change the goodness of the fit (Figure S25). 
Our previous FRET studies showed that the shorter distance observed between probes on 
the SERCA and PLB cytoplasmic domains is the R state (correlating with decreased 
inhibition), while the longer distance is due to the T state, in which the PLB cytoplasmic 
domain interacts with membrane surface and hence increases interprobe distance [84]. 
Therefore, we refer the parameters of the shorter distance with a subscript R, and those of 
the longer distance with a subscript T (Figure 19). 
 
Statistical Analysis 
Data is presented as the mean ± SE. For comparison between two groups, a 
student’s t-test was performed. A p-value less than 0.05 was taken as significant. 
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30B4.4 Results 
 
Function of labeled SERCA and PLB.  
To confirm that the labeled proteins preserve their functions, we co-reconstituted 
SERCA and PLB into lipid vesicles and measured the Ca
2+
-dependent ATPase activity. 
The function of unlabeled PLB is characterized by inhibition of SERCA (decreasing 
pKCa) and reversal after phosphorylation at S16 by PKA (Figure 20). For unlabeled 
SERCA, pKCa = 6.43 ± 0.02, unlabeled PLB shifted pKCa to 6.32 ± 0.003, and unlabeled 
pPLB restored pKCa to 6.39 ± 0.02. Labeled proteins demonstrated similar results (Figure 
20). The pKCa of acceptor-labeled SERCA is 6.45 ± 0.02, donor-labeled PLB shifted it to 
6.32 ± 0.003, and phosphorylated donor-labeled PLB shifted it back to 6.45 ± 0.01. 
Therefore, the fluorophore-labeled SERCA and PLB retained their functions, and these 
samples should provide reliable information of the conformational rearrangement 
induced by phosphorylation of S16 by PKA. 
  
A B
C
7.5 7.0 6.5 6.0 5.5
0.0
0.2
0.4
0.6
0.8
1.0
7.5 7.0 6.5 6.0 5.5
0.00
0.05
0.10
0.15
 
 PLB
 pPLB
 
Unlabeled Labeled
Unlabeled Labeled
SERCA
+ PLB
+ pPLB
pCa pCa
N
o
rm
a
li
z
e
d
 A
c
ti
v
it
y
∆
p
K
C
a
 
Figure 20: Functional effect of PLB phosphorylation (as measured by ∆pKCa) is not affected by 
FRET labeling of SERCA and PLB. The molar ratio of Lipid:PLB:SERCA is 700:5:1. n ≥ 3. 
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 TR-FRET within the SERCA-PLB complex.  
Time-resolved fluorescence of donor-labeled PLB was measured in the presence 
of either unlabeled or acceptor-labeled SERCA with a PLB to SERCA molar ratio of 0.2. 
The fluorescence waveforms were then fitted by the equations described in Materials and 
Methods. TR-FRET data was fitted to two Gaussian distance distributions [84], assuming 
that PLB and pPLB populate the same two structural states (Figure S24 and Figure S25). 
The shorter distance, rR, is 3.52 ± 0.42 nm and the longer distance, rT, is 8.27 ± 0.27 nm 
(Figure 21A&B). The distance between the labeling sites predicted by the SERCA-PLB 
model is 2.69 nm (Figure 19A right) [65]. Crosslinking showed previously that K3 of 
PLB was within 1.5 nm of SERCA K400 [54]. The distance between C674 and K400 
predicted by a crystal structure in the absence of Ca is 3.48 nm (3B9R) [20], consistent 
with our measurement for rR. The fraction of pPLB that binds to SERCA (xDA) decreased 
significantly from that of PLB, from 0.99 ± 0.01 to 0.50 ± 0.06 (Figure 21C), indicating 
that the SERCA-PLB complex partially dissociates after PLB phosphorylation. Within 
the bound population, the fraction of the R state, x
R
, is substantially increased after PLB 
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Figure 21: TR-FRET shows that phosphorylation of PLB partially dissociates the SERCA-PLB 
complex and shifts the population to the shorter distance distribution. A: Two Gaussian distance 
distributions (two structural states of SERCA-PLB, R and T) were needed to fit the TR-FRET 
data. Red: PLB. Blue: pPLB. B: Centers (r) and widths (FWHM) of distance distributions. C: 
Compared to PLB, phosphorylated PLB decreased the mole fraction of SERCA-bound PLB 
(xDA), but did not abolish it. D: The mole fraction of the short distance component (xR) increased 
after phosphorylation. SERCA: PLB = 5. Lipid : SERCA = 200. n ≥ 3. * p<0.05, ** p<0.01, 
***p<0.001.  
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phosphorylation, from 0.33 ± 0.04 to 0.68 ± 0.04 (Figure 21A&C), indicating a 
substantial shift of the T/R equilibrium toward the R state. 
Interprobe distances were measured at three Ca
2+ 
concentrations, and no 
significant effects of Ca
2+ 
were observed in binding or structure (Figure 21, Table S4). 
These results show clearly that PLB remains bound to SERCA after the E2 (Ca-free)
 
to 
E1 (Ca-bound) transition. This result is consistent with previous FRET findings that the 
SERCA-PLB complex does not dissociate at physiological Ca
2+
 concentrations [85,86]. 
 
31B4.5 Discussion 
We have performed TR-FRET on fluorophore-labeled SERCA and PLB co-
reconstituted into lipid vesicles, to probe the structural mechanism for relief of inhibition 
by PLB phosphorylation and by micromolar Ca
2+
. The functions of the proteins were 
preserved after covalent modification with fluorophores (Figure 20). TR-FRET analysis 
showed that phosphorylation of PLB partially dissociates the SERCA-PLB complex and 
shifts the SERCA-bound PLB toward the less inhibitory R state. Ca
2+
 does not dissociate 
the complex or perturb the T/R equilibrium (Figure 21). 
The mechanism of relief of inhibition due to PLB phosphorylation has been 
controversial. Phosphorylation of PLB has been found to perturb the physical interaction 
between SERCA and PLB, as detected by decreases in crosslinking [74] and co-
immunoprecipitation [75]. One study in living cells, using fluorescent fusion proteins, 
reported that phosphomimetic PLB mutations decreased FRET between SERCA and PLB 
[179], while another study reported increased FRET upon PLB phosphorylation [172]. 
Due to the steady-state nature of these FRET measurements, it is not clear whether 
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changes in FRET were due to changes in SERCA-PLB association or to changes in the 
donor-acceptor distance within the complex. In the present study, this ambiguity was 
removed by the detection of time-resolved fluorescence, which simultaneously and 
independently resolves changes in binding and structure [84]. TR-FRET showed that 40-
50% of PLB remains bound to SERCA after phosphorylation (Figure 21C), even though 
phosphorylation completely relieves SERCA inhibition (Figure 20). Therefore, the 
activity of the SERCA-pPLB complex is comparable to that of SERCA alone, and the 
relief of inhibition in the bound complex must be due to a structural change within the 
SERCA-pPLB complex.  
To assess the physiological significance of the two observed effects – dissociation 
and structural change, it is important to compare the composition of our reconstituted 
samples with those in cardiac SR. In the present study with a fluorescent donor on PLB, 
acceptor-labeled SERCA was in 5-fold excess over PLB, to maximize the precision of 
FRET measurements. However, in cardiac SR, as in our functional measurements (Figure 
20), PLB is in large excess (3-5 fold) over SERCA [26].  Based on the affinity of SERCA 
for pPLB indicated from Figure 21, and on the known concentrations of SERCA and 
PLB in cardiac SR [26,180], 76 ± 2% of SERCA in cardiac SR contains bound pPLB, 
even after complete phosphorylation of PLB (Table S5). This is consistent with EPR and 
NMR findings that pPLB remains bound to SERCA [80,171], with allosteric relief of 
inhibition achieved by shifting the T/R equilibrium toward the R state [80,83]. The 
present study clearly supports this “subunit” model for SERCA regulation (Figure 22, 
left) over the dissociation model. 
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Although both dissociation and subunit models have been proposed to explain the 
mechanism of relief of inhibition by micromolar Ca
2+
 [72,73,76,85,86], our TR-FRET 
data showed no Ca-dependent changes in either binding or structure (Figure 21B, C, D), 
clearly ruling out the dissociation model, but also showing clearly that Ca
2+ 
relieves 
SERCA-PLB inhibition by a different mechanism from that of phosphorylation. This 
result is consistent with previous steady-state FRET studies showing little or no 
dissociation of PLB from SERCA due to Ca
2+
 [85,86]. Ca
2+
 is known to induce structural 
changes in its activation of SERCA [181,182], but these changes apparently do not 
perturb the distance between our labeling sites in the cytoplasmic domains of SERCA 
and PLB. This conclusion is consistent with structural models, since the distance between 
SERCA C674 (our acceptor labeling site) and K400 (proposed to lie in the binding 
groove of the PLB cytoplasmic domain, where our donor is located), changes only from 
3.48 nm in the Ca-free crystal structure to 3.41 nm in the Ca-bound structure [16,20]. 
Since SERCA inhibition by PLB is caused by interaction of the transmembrane domains 
of the two proteins [60], we propose that Ca-induced structural changes in the SERCA 
transmembrane domain disrupt this inhibitory interaction, without changing interactions 
of the cytoplasmic domains, and without producing a substantial decrease in SERCA-
PLB affinity (Figure 22, right). This rearrangement of transmembrane helices would 
explain the Ca-induced decrease in crosslinking between the transmembrane domains of 
SERCA and PLB [72,73,76]. 
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In summary, we conclude that phosphorylation of PLB and Ca
2+ 
relieve SERCA 
inhibition through different mechanisms (Figure 22), neither of which relies primarily on 
dissociation of the SERCA-PLB complex. PLB phosphorylation acts by promoting the 
dynamic disorder of the PLB cytoplasmic domain, while Ca
2+
 acts by changing the 
structure of the transmembrane domain of SERCA. Both mechanisms must disrupt the 
inhibitory interactions between the two transmembrane domains, by distinct mechanisms 
that remain to be elucidated (Figure 22). 
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Figure 22: Two mechanisms to relieve SERCA inhibition by PLB in cardiac SR.  
Phosphorylation shifts the PLB cytoplasmic domain toward the dynamically disordered R state. 
Micromolar Ca
2+
 induces a structural change in the SERCA transmembrane domain. 
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Figure S23: Two lifetimes are sufficient to fit the time-resolved fluorescence data. Both residual 
and χ2 values decreased significantly from 1 lifetime to 2 lifetimes, but did not improve 
appreciably with a third lifetime. A Time-resolved fluorescence waveform of a donor only 
sample. B Residual plots of 1 lifetime (black), 2 lifetimes (red), and three lifetimes (blue). C χ2 
values with 1, 2, or 3 lifetimes.  
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Figure S24: Results from independent fits, assuming that PLB and pPLB populate different 
structural states, each characterized by a 2-Gaussian interprobe distance distribution (Equation 
25, illustrated in Figure 19C).  Phosphorylation (A) partially dissociates the complex (deceases 
x
DA
, defined in Equation 23), and (D) increases the population of the R state within the complex 
(increases x
R
). The centers (rR and rT) and widths (FWHMR and FWHMT) resolved from 
independent fits are similar in the presence and absence of phosphorylation. This observation 
justifies the global fits in Figure 21, where we assumed that PLB and pPLB populate the same R 
(rR and FWHMR) and T (rT and FWHMT) states. *p < 0.05.  
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Figure S25: Comparisons among different fitting models, for PLB (red) and pPLB (blue). The 
residual and χ2 values are greatly improved from 1 Gaussian to 2 (Equation 24 & Equation 25). 
With the same distances assumed (The same two structural states are present for PLB and pPLB, 
only the mole fractions change.), the χ2 value did not change compared to that of the independent 
2-Gaussian fitting (Figure S24). However, when we forced the fraction bound (x
DA
) to be the 
same, the residual and χ2 value worsened appreciably. Therefore, we reported the results of 2 
Gaussian fitting with same distances assumed in Figure 21. 
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Table S4 Interprobe distances.  
  x
DA
 x
T
 r
T
 (nm) 
FWHM
T 
(nm) 
x
R
 r
R 
(nm) 
FWHM
R 
(nm) 
pCa 
8.0 
PLB 
1.00 ± 
0.01 ** 
0.67 ± 
0.04 *** 
8.37 ± 
0.21 
2.97 ± 
1.18 
0.33 ± 
0.04 
3.55 ± 
0.30 
2.56 ± 
0.78 
 pPLB 
0.50 ± 
0.06 
0.32 ± 
0.03 
  
0.68 ± 
0.03 
  
pCa 
6.4 
PLB 
0.97 ± 
0.02 ** 
0.71 ± 
0.03 * 
8.14 ± 
0.17 
2.25 ± 
0.56 
0.29 ± 
0.03 
3.45 ± 
0.08 
2.09 ± 
0.24 
 pPLB 
0.40 ± 
0.09 
0.28 ± 
0.07 
  
0.72 ± 
0.07 
  
pCa 
5.4 
PLB 
0.86 ± 
0.09 * 
0.77 ± 
0.08 * 
7.68 ± 
0.57 
2.28 ± 
0.44 
0.23 ± 
0.08 
3.44 ± 
0.17 
1.94 ± 
0.46 
 pPLB 
0.43 ± 
0.05 
0.44 ± 
0.05 
  
0.56 ± 
0.05 
  
* p <0.05, ** p < 0.01, *** p < 0.001 compared to pPLB at the same Ca
2+
 concentration. 
Assumed that PLB and pPLB populate the same R (r
R
 and FWHM
R
) and T (rT and FWHMT) 
states. 
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      Table S5 Mole fraction of SERCA containing bound pPLB, xB 
Samples [SERCA]t [pPLB]t xB 
TR-FRET 5 1 0.09 ± 0.01 
Activity Assay 1.4 7 0.53 ± 0.03 
Cardiac SR 6.5 22.7 0.76 ± 0.02 
    
PLB was assumed to be completely phosphorylated. [SERCA]t and [pPLB]t are the total 
concentrations, expressed in molecules per 1000 lipids. For the TR-FRET samples, xB = 
0.09 was calculated from xDA, the fraction of donor-labeled pPLB molecules containing 
bound SERCA (Figure 21C), using xB = xDA[pPLB]t / [SERCA]t. (No statistically 
significant difference was found as a function of pCa, so we used the average value of 
xDA = 0.45 ± 0.04 for pPLB in Figure 21C). The concentrations of total SERCA 
([SERCA]t) and total pPLB ([pPLB]t) are either controlled in the samples for TR-FRET 
and activity assays, or estimated from reported values in cardiac SR [26,183]. SERCA-
SERCA and PLB-PLB interactions are neglected, since they are much weaker than 
SERCA-PLB interactions [36]. The SERCA and pPLB binding affinities are assumed to 
be the same under the three conditions. Kd is calculated to be 6.0 ± 0.8 per 1000 lipids, 
using the parameters resolved from TR-FRET data and the equation  
 
The fractions of pPLB-bound SERCA in the activity assay and in cardiac SR are 
estimated using the following equations: 
 
 
  
   
             
            
 
             
                      √                                       
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33B5.1 Chapter Overview 
We have studied the differential effects of phospholamban (PLB) phosphorylation 
states on the activity of the sarcoplasmic reticulum (SR) Ca-ATPase (SERCA). It has been 
shown that unphosphorylated PLB (UPLB) inhibits SERCA and that phosphorylation of 
PLB at S16 or T17 relieves this inhibition in cardiac SR. However, the levels of the four 
phosphorylation states of PLB (UPLB, singly phosphorylated P16-PLB and P17-PLB, and 
doubly phosphorylated 2P-PLB) have not been measured quantitatively in cardiac SR, nor 
have their functional effects on SERCA been determined directly. Therefore, we 
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synthesized all four PLB species and used them as standards to establish a quantitative 
immunoblot assay. This assay was used to determine the mole fractions of all four PLB 
phosphorylation states in pig cardiac SR. To determine directly the functional effects of 
each PLB species, we co-reconstituted each of the synthetic peptides in phospholipid 
vesicles with SERCA1a, and measured the Ca
2+ 
dependence of SERCA activity. SERCA 
inhibition, measured as the decrease in apparent Ca
2+ 
affinity, was maximally relieved by 
P16-PLB, followed by 2P-PLB, followed by P17-PLB. Thus, phosphorylation at T17 
showed the least capacity to relieve SERCA inhibition, and actually decreased the effect 
of phosphorylation at P16 on the same PLB. These results show that each PLB 
phosphorylation state uniquely alters Ca
2+ 
homeostasis, with important implications for 
cardiac health, disease and treatment. 
 
34B5.2 Introduction 
The role of PLB and PLB phosphorylation in cardiac calcium homeostasis - 
During cardiac relaxation, the sarcoplasmic reticulum calcium ATPase (SERCA) actively 
transports calcium into the SR. The resulting electrochemical gradient supplies most of 
the driving force for passive Ca
2+ 
 efflux into the cytosol during contraction [1]. In 
cardiac sarcoplasmic reticulum (CSR), SERCA forms a complex with its inhibitor, 
phospholamban (PLB) [1,67,137,184]. It has been shown that an increase in the ratio of 
unphosphorylated phospholamban (UPLB) to SERCA, by overexpression of PLB or 
decreased phosphorylation, decreases the apparent Ca
2+ 
affinity (pKCa) of SERCA and 
leads to contractile dysfunction [185,186]. Phosphorylation at S16 and/or T17 [47,187] 
partially reverses this inhibition by increasing the apparent Ca
2+ 
affinity of SERCA 
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[185,188,189]. Spectroscopic studies show that PLB phosphorylation induces structural 
rearrangement within the PLB/SERCA complex without changing the affinity of SERCA 
for PLB, which is essentially a subunit of SERCA under physiological conditions 
[171,190]. Having ruled out a dissociative mechanism for relieving SERCA inhibition, 
PLB phosphorylation emerges as the molecular switch that regulates SERCA activity 
[83]. However, this is a complex switch, because there are four distinct PLB 
phosphorylation states: UPLB (no phosphorylation, favored by protein phosphatase-1, 
PP1 [191,192,193]), P16-PLB (phosphorylation at Ser16 by protein kinase A [194]), P17-
PLB (phosphorylation at Thr17 by CaMKII), and 2P-PLB (phosphorylation at both Ser16 
and Thr17). Their regulation of SERCA depends on two factors: (a) the concentration of 
each state (b) the potency of each as a SERCA-bound inhibitor, pKCa. 
Quantitation of the four PLB phosphorylation states – It has been proposed that 
the concentration of each PLB phosphorylation state differs with the etiology of heart 
disease. Qualitative western blots have suggested that P16-PLB and P17-PLB 
concentration decrease in dilated cardiomyopathy [195] and that P17-PLB concentration 
increases in ischemia [196] and acidosis [197]. 2P-PLB has not been measured. 
Moreover, these trends can vary with age [198] and gender [199]. A complete 
phosphorylation profile for each age group, gender, and etiology of heart failure could 
guide rational design of disease-specific phosphomimetic mutants [172], targeted toward 
the proper PLB phosphorylation state. Such a phosphorylation profile can also evaluate 
PP1, CaMKII, and PKA as targets for small molecules [200,201]. Assessing the role of 
PLB phosphorylation states in cardiac pathology and treatment will require quantitation 
of their concentrations. Quantitation of PLB phosphorylation states has been hindered by 
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the availability of appropriate antibodies. Antibodies to 2P-PLB have become available 
only recently, and none of the PLB antibodies that are selective for other phosphorylation 
states are completely specific [202]. Thus, quantitation of PLB phosphorylation states has 
not been accomplished. 
The functional effects of PLB phosphorylation states – The inhibitory potency of 
each phosphorylation state determines its functional effect at a given concentration. 
Previously, PP1, PKA, and CaMKII have been used in efforts to phosphorylate PLB 
selectively at S16 or P17, but complete and exclusive phosphorylation at one site was 
never achieved, so the only clear conclusion was that both P16-PLB and P17-PLB show 
decreased SERCA inhibition [47,203,204,205,206,207,208,209]. The effect of double 
phosphorylation (2P-PLB) is controversial. In one study, addition of a second phosphate 
increased the pKCa [210], while in two other studies, it had no effect [47,211]. Thus the 
inhibitory potencies of the four PLB phosphorylation states are yet to be determined. 
The present study - In the present study, we have used solid-phase peptide 
synthesis to produce pure samples of each of the four PLB phosphorylation states, 
allowing the accurate quantitation of both the concentration and potency of each PLB 
phosphorylation state. To measure concentrations, the four synthetic peptides were used 
as standards to quantify antibody selectivity, enabling the accurate determination of all 
four species by immunoblot, despite the imperfect specificities of the four antibodies. To 
measure the potency of each PLB phosphorylation state, pKCa was measured after each of 
the four synthetic peptides was co-reconstituted with SERCA, guaranteeing complete, 
exclusive, and site-specific phosphorylation, as well as identical PLB/SERCA 
stoichiometry. 
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35B .3 Experimental Procedures 
Synthesis of the four phosphorylation states of PLB – The sequences of human 
UPLB, P16-PLB, P17-PLB, and 2P-PLB were prepared using Fmoc solid-phase peptide 
synthesis with or without incorporation of phosphorylated amino acids at specific sites 
[78,83]. Phosphorylation was accomplished by incorporation of Fmoc-
Ser(PO(OBzl)OH)-OH for P16-PLB and Fmoc-Thr(PO(OBzl)OH)-OH for P17-PLB 
during peptide synthesis. 2P-PLB was prepared by incorporation of both phosphorylated 
amino acids at position S16 and T17 [78,83]. UPLB was prepared without incorporation 
of phosphorylated amino acids. Phospholamban was characterized by amino acid analysis 
and mass spectrometry [78].  
SERCA1a was purified from rabbit skeletal muscle using reactive red in 0.1% 
octaethylene glycol monododecyl ether (C12E8) as previously described [85,174]. And 
the concentration was measured with the Pierce BCA assay [78,83].  
Electrophoresis and immunoblot-Samples were dissolved in Laemmli buffer 
(Biorad) with 5% -mercaptoethanol (BME), loaded onto a 10-20% Tris-Tricine gel 
(Biorad), and separated by SDS-PAGE at constant voltage (120V) at 25 
o
C for 90 minutes. 
Proteins were then transferred to 0.45 micron Immobilon-FL PVDF membranes (Millipore) 
in Towbin transfer buffer [212] for 50 minutes at constant current (300mA), blocked 
overnight in pure Odyssey blocking buffer (LI-COR Biosciences), and rinsed for 1 minute 
in ddH2O. Each membrane was incubated with one primary antibody (Ab) per the 
manufacturer’s instructions, washed 3 times for 15 minutes with TBST (Tris-buffered 
saline with 0.1% tween) and then incubated with a second primary antibody per the 
manufacturer’s instructions, and washed 3 times for 15 minutes with TBST before 
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simultaneously adding two secondary antibodies LI-COR IR-680LT and LI-COR 800CW, 
directed against the appropriate animal, each at a dilution of 1:15,000 for 25 minutes. The 
membrane was then washed 3 times for 15 minutes with TBST, and the blots were stored in 
TBS (Tris-buffered saline). Proteins were detected and analyzed using the LI-COR 
Odyssey. The 700nm channel detected the IR-680LT and the IR-680RD. The 800nm 
channel detected the IR-800CW (LI-COR Biosciences). All incubation buffers consisted of 
50% Odyssey blocking buffer (LI-COR Biosciences) and 50% TBS containing 0.1% Tween 
20 (TBST) except the incubation of the antibody for 2P-PLB. This was incubated in 5% 
w/v BSA, 1X TBS, 0.1% Tween-20 at 4°C, per the manufacturer’s instructions. Analysis 
by densitometry was accomplished with Odyssey software. The resolution was 169 μm and 
the focus offset was 0.0 mm. Boxes were drawn around an area that encompassed all PLB 
bands (monomeric and oligomeric). The background was local, determined as the average or 
median of the intensities at the top and the bottom of the box. The greatest linearity was 
obtained at a border width of 1 pixel. 
 
Table 6. Primary antibodies. Indices (i) and (j) correspond to antibodies and PLB species, 
respectively in Equation 26. 
Antibody Epitope Ab 
abbrev (i) 
PLB 
selectivity (j) 
reactivity dilution company 
2D12 1-52 AbU (1) UPLB (1) Mouse 1:6000 Abcam 
Ab12963 11-21 Ab16 (2) P16-PLB and 
2P-PLB (2) 
Goat 1:1000 Santa Cruz 
Biotechnology 
Ab17024-
R  
12-22 Ab17 (3) P17-PLB  and 
2P-PLB (3) 
Rabbit 1:1000 Santa Cruz 
Biotechnology 
Ab8496 unknown Ab2P (4) 2P-PLB (4) Rabbit 1:2000 Cell Signaling 
Technology 
*Cell Signaling Technology reports that the Ab8496 epitope has 100% sequence homology with 
pig and human, thus excluding E2D and K27N. 
 
Quantification of four  phosphorylation states of PLB - Quantitation of the four 
phosphorylation states of PLB in pig cardiac SR was accomplished by an extension of our 
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previous method for quantitation of two states [202], using the antibodies given in Table 6. 
Antibodies entirely specific for each of these four species are not available, so it is necessary 
to start with four antibodies having partial selectivity, determine this selectivity 
quantitatively using purified synthetic standards, run the unknown on the same four blots, 
and then solve a system of four equations with four unknowns to determine the composition 
of the unknown sample (Equation 26): 
Ii = Σεijcj , I = 1, …4; j = 1, …4, Equation 26 
i refers to the primary antibody, and j refers to the phosphorylation state of the standard, 
as defined in Table 6. Thus ɛij is the slope of the standard curve from phosphorylation 
state j (obtained using purified synthetic standards) from a blot using primary antibody i, 
and cj is the concentration of the phosphorylation state j of PLB in the sample. The result 
is a 4x4 matrix of simultaneous equations, which was solved in MATLAB, to determine 
the unknown concentration cj. The mole fraction of each PLB phosphorylation state (Xj) 
was calculated from  
Xj = cj/Σcj (j = 1, …4), Equation 27 
To validate the method, it was applied to mixtures of synthetic standards 
containing known concentrations of each phosphorylation state (Table 7). The PLB 
primary antibodies were all based on epitopes that exclude residues 2 and 27 (the only 
differences between human and pig sequences), so the method is equally valid for analysis 
of both species. Secondary antibodies Ab800CW (goat-anti mouse), Ab800CW (donkey- 
anti goat), and Ab680LT (goat anti-rabbit), were obtained from Li-COR Biosciences. 
Quantitation of SERCA was accomplished by SDS-page, stained with coomassie brilliant 
blue, using purified SERCA1a. 
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Table 7. Known Xj values (Equation 27) in mixtures of PLB 
standards 
Mixture U P16 P17 2P n 
a 0.25 0.25 0.25 0.25 6 
b 0.10 0.20 0.30 0.40 6 
c 0.20 0.30 0.40 0.10 6 
d 0.30 0.40 0.10 0.20 6 
e 0.40 0.10 0.20 0.30 6 
 
ATPase assay-Ca-ATPase activity was performed after reconstitution of SERCA 
with each of the four synthetic PLB standards [60,78,83,213,214]. PLB and SERCA were 
reconstituted in dioleoyl-phosphatidylcholine (DOPC) and dioleoyl-
phosphatidylethanolamine (DOPE), at a molar ratio of 4:1 as previously described [148], 
at a molar ratio of PLB/SERCA/lipid of 5/1/700. Ca-ATPase activity was measured as a 
function of [Ca
2+
] using an NADH-coupled, enzyme-linked ATPase assay [84,85] at a 
temperature of 25
o
C. The data were fitted by the Hill equation: 
V = Vmax/[1+ 10
–n (pKCa – pCa)
] Equation 28 
Vmax is the maximum ATPase rate; pKCa is the apparent Ca affinity; and n is the 
Hill coefficient. Inhibitory potency of each PLB species is defined as pKCa, the decrease 
in pKCa compared with that measured with SERCA in the absence of PLB.  
Statistical analysis - For validation of the method, the accuracies of XPLB values, 
performed on known mixtures of standards, were calculated as ∆XPLB, which is equal to 
∆XPLB(apparent) - ∆XPLB. Precision is expressed as SEM. XPLB in pig CSR and pKCa in 
the co-reconstitutions were compared using one-way analysis of variance (ANOVA). A 
p-value of less than 0.05 was considered significant.  
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36B5.4 Results 
Validation of immunoblot method  The assay was applied to five mixtures of 
synthetic standards containing known concentrations of each of the four PLB 
phosphorylation states (Table 7). Four identical gels, with the same concentrations of 
each pure synthetic PLB standard and equal volumes of the same five mixtures (Table 7) 
were run and blotted with four different antibodies. The mixtures were run in duplicate. 
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Figure 26. Validation of the method for calculating mole fractions (XPLB, Equation 27) of all 
four PLB phosphorylation states. (A) Immunoblots stained with two primary antibodies. (B) 
Individual images from A. Numbers in parentheses indicate i and j values in Equation 26 and 
Table 6. (C) Standard curves produced from intensity values Ii (i indicates the antibody as in B), 
obtained from densitometry of standards in B. Slopes are the εij values in Equation 26. (D) The 
error ΔXPLB, obtained from mixtures (Table 7), plotted against the actual XPLB for all four PLB 
phosphorylation states. 
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The use of fluorescent secondary antibodies made it possible to visualize two blots on the 
same membrane (Figure 26A), provided that the primary antibodies were produced in 
different animals. For the top blot in Figure 26A, mouse primary antibody (AbU) was 
paired with rabbit primary antibody (Ab17). For the bottom blot in Figure 26A, goat 
primary antibody (Ab16) was paired with rabbit primary antibody (Ab2P). Visualizing 
two different epitopes on one membrane required that the secondary antibodies emitted at 
resolved wavelengths. LI-COR800CW is conjugated to a dye detected at 800 nm, using a 
green pseudo-color for display. By contrast, LI-COR680LT is conjugated to a dye 
detected at 680 nm, using a red pseudo-color for display. In Figure 26A (top), the green 
signal corresponds to goat-anti-mouse-LI-COR-800CW secondary antibody bound to 
primary mouse antibody AbU, and the red signal corresponds to goat-anti-rabbit-LI-
COR-680LT secondary antibody bound to primary rabbit antibody Ab17. In Figure 26A 
(bottom), the green signal corresponds to donkey-anti-goat-LI-COR-800CW secondary 
antibody bound to primary goat antibody Ab16, and the red signal corresponds to goat-
anti-rabbit-LI-COR-680LT secondary antibody bound to primary rabbit antibody Ab2P. 
Figure 26B shows the red and green signals resolved in separate images. 
Figure 26C shows standard curves obtained from the 2.5, 5, and 11 ng PLB 
standards in Figure 26B. In C, “Ii” indicates the primary antibody that was used to stain 
the corresponding blot in B (see Table 6), and the slopes of these standard curves are the 
ɛij values in Table 6 and Equation 26. All slopes had a Pearson’s r value of ≥ 0.95. These 
ɛij values were used to calculate the mole fraction of each species in the five mixtures, 
and the results are compared with the known values, in Figure 26D and Table 8. ΔXPLB is 
the difference between the measured and known mole fractions in the PLB mixtures. The 
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results show that the assay is remarkably accurate, with all 20 measurements coming 
within 0.1 of the correct value. 
Table 8. ΔXPLB values in mixtures of PLB standards, mean ± SEM (Figure 26D) 
 UPLB P16-PLB P17-PLB 2P-PLB n 
a 0.02 ± 0.02 -0.01 ± 0.04 -0.03 ± 0.02 0.01 ± 0.02 6 
b -0.05 ± 0.02 -0.08 ± 0.02 0.01 ± 0.01 0.03 ± 0.01 6 
c 0.00 ± 0.01 -0.07 ± 0.01 0.07 ± 0.01 0.04 ± 0.10 6 
d 0.05 ± 0.01 -0.10 ± 0.01 -0.05 ± 0.00 0.02 ± 0.01 6 
e -0.02 ± 0.01 -0.10 ± 0.02 0.07 ± 0.02 0.04 ± 0.05 6 
 
Application to Cardiac SR  The mole fractions (XPLB), of all four phosphorylation 
states of PLB were measured in cardiac sarcoplasmic reticulum prepared from six pig 
hearts, using the method described in Figure 26. The greatest mole fraction was observed 
for P16-PLB (XP16 = 0.45 ± 0.008), followed by UPLB (XUPLB = 0.35 ± 0.008), then the 
doubly phosphorylated 2P-PLB (X2P = 0.12 ± 0.006); P17-PLB had the lowest 
concentration in CSR (XP17 = 0.08 ± 0.007) (Figure 27, right). ANOVA showed 
significant differences among all the mole fractions of PLB phosphorylation states. In 
summary, all four states are significantly populated, and the order of mole fractions is 
P16-PLB > UPLB >> 2P-PLB > P17-PLB. 
Effects of specific phosphorylation states of PLB on SERCA activity    Synthetic 
human UPLB, P16-PLB, P17-PLB, and 2P-PLB were evaluated for their ability to inhibit 
SERCA (Figure 28). By fitting the data with Equation 28, the inhibition of Ca-ATPase 
activity was quantified by the decrease in pKCa (the negative log of the pCa value 
required for 50% activation) in Figure 28A. Each PLB phosphorylation state displayed a 
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significantly different value of pKCa, according to the ANOVA, showing that they are 
functionally distinct. As expected, UPLB, the constituent inhibitor of SERCA showed the 
largest decrease in pKCa compared to SERCA alone. When compared to UPLB + 
SERCA, P16-PLB had the largest increase in pKCa, followed by 2P-PLB and lastly, P17-
PLB (Figure 28). Thus, the order of SERCA restorative potency of the phosphorylated 
derivatives of PLB is P16-PLB >> 2P-PLB > PThr17 (Figure 28). 
 
37B5.5 Discussion 
Quantitation of PLB phosphorylation states in cardiac SR   We have extended our 
previous quantitative immunoblot assays [202], which measured mole fractions of two PLB 
phosphorylation states, to measure mole fractions of all four PLB phosphorylation states 
(Figure 26). Our assay allows accurate quantitation even though Ab16 and Ab17 are not 
completely specific (Figure 26C). The use of the synthetic peptides and two-color 
immunoblots provides accurate concentrations of all four species in known mixtures 
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Figure 27. Mole fractions of PLB phosphorylation states in SR isolated from pig hearts. 
Mean ± SEM, n = 6 hearts. 
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(Figure 26D). We used this assay to determine the unknown concentrations of these 
phosphorylation states of PLB in pig cardiac SR, showing that all four states are present, 
with the concentration of P16-PLB comparable to that of UPLB, 4 times that of 2P-PLB, 
and 6 times that of P17-PLB (Figure 27). In the future, this assay can be used to investigate 
correlations between the mole fractions of PLB phosphorylation states (Figure 27) and 
cardiac physiology and pathology, as affected by CaMKII, PKA, and PP1. 
Direct measurement of inhibitory potencies of all four PLB phosphorylation states - 
We have used four phosphorylation state-specific co-reconstitutions of PLB with SERCA 
to determine the inhibitory potencies of PLB phosphorylation states (Figure 28). Our in 
vitro system has facilitated the simultaneous control of PLB/SERCA stoichiometry and 
the purity of each PLB phosphorylation state, which is not feasible in cardiac tissue 
samples (Figure 27)[47]. While our assay utilizes SERCA1a from fast-twitch skeletal 
muscle, our measured potencies apply as well to the heart, where SERCA2a predominates, 
since these two isoforms have been shown to have identical regulatory interactions with 
PLB [215,216]. 
Each PLB phosphorylation state has a distinct effect on SERCA function (Figure 
28, Table 9). These differences are not due to differences in affinity for SERCA, since the 
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Figure 28. SERCA activity due to PLB phosphorylation states. SERCA (black), UPLB (red), 
P16-PLB (blue), P17-PLB (green), 2P-PLB (cyan). (A) Ca-ATPase data, showing best fits to 
Equation 28, with data normalized to the Vmax value obtained in the fit. (B) pKCa values from A. 
(C) pKCa values, relative to no PLB. 
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PLB/SERCA ratio of 5/1 used here was previously determined to be saturating, 
independent of PLB phosphorylation [149,171]. UPLB increased pKCa by 0.40, 
corresponding to an increase of KCa by a factor of 2.5. P16-PLB was the least inhibitory 
PLB species, increasing pKCa by only 0.23. Thus phosphorylation at P16 has the greatest 
effect in relieving SERCA inhibition. Intermediate results were observed for P17-PLB 
(pKCa = 0.36) and for 2P-PLB (pKCa = 0.30) (Figure 28, Table 9), showing that the 
effects of phosphorylation at the two sites are not additive, since double phosphorylation 
produces an effect intermediate between the two singly phosphorylated states of S16 
phosphorylation when both S16 and T17 are phosphorylated on the same PLB (Figure 28, 
Table 9).  
Implications for cardiac physiology and pathology    An established therapeutic 
goal in treatment of heart failure is SERCA activation [217]. Therefore, the low inhibitory 
potency of P16-PLB (Table 9) establishes it (not P17-PLB or P2-PLB) as the best template 
for loss-of-inhibition PLB mutants in gene therapy [123,149,172,218]. Similarly, these 
results suggest that activation of PKA should be therapeutically more effective than 
activation of CaMKII. In fact, elevation of CaMKII activity could reduce the benefits of 
Table 9. Effect of PLB on SERCA activity (Figure 28), mean ± SEM. 
Sample KCa (M) pKCa ∆pKCa n 
no PLB 0.20 ± 0.01 6.70 ± 0.01 0 4 
UPLB 0.50 ± 0.09 6.30 ± 0.02 0.40 ± 0.03 4 
P16-PLB 0.34 ± 0.04 6.47 ± 0.01 0.23 ± 0.02 4 
P17-PLB 0.40 ± 0.04 6.34 ± 0.01 0.36 ± 0.02 4 
2P-PLB 0.36 ± 0.40 6.40 ± 0.01 0.30 ± 0.02 4 
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PKA activation, since both P17-PLB and 2P-PLB are more inhibitory than P16-PLB 
(Table 9). This may explain why the P17-PLB elevation at the onset of ischemia fails to 
improve SERCA activity and cardiac function [197]. The low inhibitory potency of P17-
PLB can also be therapeutically useful. For example, in acidosis and ischemia, where 
elevated CaMKII leads to arrhythmia, necrosis and apoptosis [197], treatment with small-
molecule CaMKII inhibitors [219,220] can occur without appreciable decreases SERCA 
activity.  
Conclusions We have used solid-phase peptide synthesis to produce pure samples 
of each of the four PLB phosphorylation states, making possible the accurate quantitation 
of both the concentration and potency of each PLB phosphorylation state. These four 
states are all present in pig cardiac tissue in different concentrations, and each has a distinct 
inhibitory effect on SERCA activity. Thus it is now feasible to determine these 
concentrations in human tissue samples and to relate them quantitatively to cardiac 
physiology and pathology, providing essential information for future therapeutic 
developments. 
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Chapter 6 Summary and Future Directions 
6.1 Summary 
The structural mechanism of SERCA regulation by PLB remains elusive. Two 
models have been proposed and each model has been supported with experimental 
results. The canonical “dissociation” model maintains that inhibition is caused by PLB 
binding to SERCA. For relief of inhibition to occur, PLB must dissociate from SERCA. 
The “subunit” model states that PLB acts as a subunit of the SERCA-PLB complex. The 
inhibitory potency of PLB is determined by its conformation within the complex.  
This thesis work helps elucidate the structure-function relationship of the 
SERCA-PLB complex using TR-FRET. In Chapter 3, we confirmed that the cytoplasmic 
domain of PLB equilibrates between an ordered T state and a disordered R state. By 
modulating the T/R equilibrium by electrostatic interactions, we found that the inhibitory 
potency of PLB is strongly correlated with its structural state, but not with binding. This 
study clearly supported the subunit model and established that the T state is more 
inhibitory, and that the R state is less inhibitory. In Chapter 4, I studied the SERCA-PLB 
complex with physiological perturbations: phosphorylation of PLB at Ser16 and 
micromolar Ca
2+
. TR-FRET measurements showed that Ser16 phosphorylation relieves 
inhibition both by dissociating the complex and by shifting the T/R equilibrium toward 
the less inhibitory R state, supporting both the dissociation model and the subunit model. 
In cardiac SR, the subunit model probably accounts for most of the relief of inhibition 
induced by phosphorylation. Ca
2+
 relieves inhibition through a different structural 
mechanism. Ca
2+
 is known to induce a SERCA conformational change but this protein 
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structural change did not affect the interaction between the cytoplasmic domains of 
SERCA and PLB. Hence, Ca
2+
 probably relieves inhibition by inducing structural 
rearrangements in the transmembrane domains of the complex.  
PLB can be phosphorylated at two sites, Ser16 and Thr17, generating four 
phosphorylation states: unphosphorylated, phosphorylated at Ser16, phosphorylated at 
Thr17, and phosphorylated at both sites. In Chapter 5, using a quantitative western blot 
method, we found that all of the four phosphorylation states of PLB exist in pig cardiac 
SR. We also measured the function of SERCA in the presence of different 
phosphorylation states of synthetic PLB in co-reconstituted system, and found that each 
PLB species has a distinct inhibitory potency. 
 
6.2 Future Directions 
This thesis work helps resolve the seemingly contradictory models used to explain 
the structural mechanism of SERCA regulation by PLB. Results from Chapter 3 and 4 
support the subunit model. However, the structural rearrangement in the transmembrane 
domain that disrupts the inhibitory interaction between SERCA and PLB remains elusive. 
Future spectroscopic studies should study the interactions in this critical region by 
attaching the labels in the transmembrane domain. Smaller probes, such as spin labels 
used in EPR studies, will be preferred because they have a small propensity for disturbing 
the function.  
It is an interesting finding that different phosphorylation states of PLB have 
distinct functional effects. The structural aspects of unphosphorylated and Ser16 
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phosphorylated PLB have been extensively studied, which is not the case for Thr17 
phosphorylated and doubly phosphorylated PLB. To discover the structural mechanisms 
underlying their distinct functions, the dynamics should be studied by EPR, and the 
specific interaction between SERCA and different phosphorylation states of PLB should 
be elucidated by time-resolved or single-molecule FRET.  
We used a co-reconstituted system because the lipid compositions, protein species 
and protein concentrations can be accurately controlled. The results we observed in this 
artificial system will need to be confirmed by experiments done in their native 
environment. TR-FRET should be applied to SERCA and PLB fused with fluorescent 
proteins expressed in cardiomyocytes. With electrical pacing and other physiological 
stimuli, we should be able to study the SERCA-PLB complex in action. 
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